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1. Introduction 
1.1. Superoxide dismutase 
Superoxide dismutases (SODs) are a group of metalloenzymes that are found 
in all kingdoms of life. SODs form the front line of defence against reactive oxygen 
species (ROS) mediated injury (Kangralkar et al., 2010). These proteins catalyze the 
dismutation of superoxide anion free radical (O2-) into molecular oxygen and 
hydrogen peroxide (H2O2) at a diffusion limited rate, and decrease O2- level which 
damages the cells at excessive concentration (Yasui and Bava, 2006). This reaction is 
accompanied by alternate oxidation-reduction of metal ions present in the active site 
of SODs (McCord et al., 1969; Tainer et al., 1983). 
  O2- is continuously formed in aerobic organisms because of several biological 
processes which include aerobic respiration, oxidative phosphorylation, 
photosynthesis, substrate oxidation and during immune response of stimulated 
macrophages and neutrophils. Neutrophils and macrophages are the common 
phagocytes that use O2- against the attack of various pathogens (Fridovich, 1986; 
Johnston et al., 1978). O2- and other ROS exist in biological systems at low but 
measurable concentrations (Sies, 1993). Their concentrations depend on the balance 
between their rates of production and their rates of clearance by various antioxidant 
systems. ROS plays a dual role as both beneficial and deleterious species, as they can 
be either beneficial or harmful to living systems (Valko et al., 2006). Physiological 
concentration of ROS including O2- is sparingly advantageous for all organisms (Das, 
1993). Various biochemical processes such as intracellular messaging during the cell 
differentiation and cell progression or in the arrest of growth and apoptosis (Ghosh 
and Myers, 1998) and defence by polymorphonuclear leukocytes against pathogens 
(Cleveland, et al., 2000; Das, 1993), induction of mitogenic response are dependent 
on the low/moderate concentration of ROS. Unbalanced and elevated concentrations 
of ROS result in oxygen toxicity and are responsible for oxidative stress. Continuous 
oxidative stress may have significant adverse effects on the cell structure and 
functions, and may also bring about somatic mutations and neoplastic transformation 
in the cell (Fang et al., 2009; Khandrika et al., 2009).  
Antioxidants play a key role in controlling cellular ROS levels and work not to 
remove oxidants entirely, but instead to keep them in a checked and balanced level 
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(Rhee, 2006). Antioxidants continuously scavenge ROS and include enzymatic as 
well as nonenzymatic molecules. SODs are very important antioxidant defence 
against oxidative stress in the body (Landis and Tower, 2005). Disruption of their 
functions are associated with several human diseases such as arteriosclerosis (Kakko 
et al., 2003), diabetes mellitus (Haskins et al., 2004; Ookawara et al., 1992), Down 
syndrome (Engidawork and Lubec, 2001), etc. The high concentration of SOD is 
required to effectively compete for O2- in the presence of nitric oxide which is also 
present as an important biological molecule in the cell and reacts with O2-  rapidly 
(Palmer et al., 1987; Kissner et al., 1998).   
1.1.1. Types of SODs 
Based  on the metal cofactors present in the active sites, SODs can be 
classified into four distinct groups: Copper-Zinc SOD (Cu,Zn-SOD), Iron SOD (Fe-
SOD), Manganese SOD (Mn-SOD), and Nickel SOD (Ni-SOD) (Miller et al., 2001; 
Youn et al., 1996). The different forms of SODs are unequally distributed throughout 
all biological kingdoms and are located in different subcellular compartments. The 
different forms of SODs are unequally distributed throughout all biological kingdoms 
and are located in different subcellular compartments. The Cu,Zn-SOD is found 
mainly in eukaryotes, chloroplast and bacteria (Sturtz et al., 2001). Inside the 
eukaryotic cell, Cu,Zn-SOD occurs in the cytoplasm and outer mitochondrial space 
(Sturtz et al., 2001). In addition, an extracellular Cu,Zn-SOD has been identified by 
some researchers in extracellular fluids including plasma, lymph and synovial fluid 
(Marklund et al., 1982; Faraci & Didion, 2004). Mn-SOD is also found in all cells 
exposed to oxygen, from bacterial cells to humans. In bacteria, it is found in the 
cytosol, while in eukaryotes, it is found to be located in mitochondrial matrix (Abreu 
and Cabelli, 2010). In the aerobic halophyles, SODs are Mn-SODs (Cannio et al., 
2000), which have greater resemblance to the mitochondrial Mn-SODs, as compared 
to the bacterial Mn-SODs (Fink and Scandalios, 2002). Fe-SOD is found in both 
oxygenic as well as anoxygenic photosynthetic bacteria (Paumann et al., 2002; Li et 
al., 2002) and also in some green plants (Van Camp et al., 1990; Miller, 2012). Ni-
containing SOD has been isolated from a number of Streptomyces bacteria including 
Streptomyces griseus and S. coelicolor (Youn et al., 1996; Kim et al., 1996). 
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1.1.2. Cu,Zn-SOD 
1.1.2.1. Occurrence  
Gram-negative bacteria contain Cu,Zn-SOD in their periplasmic space (Gort et 
al., 1999). This enzyme is not found in protists (Miller, 2012). Higher organisms such 
as plants, animals and fungi all possess Cu,Zn-SOD (Miller, 2012). In the yeast cell, 
Cu,Zn-SOD occurs in both cytoplasm and mitochondrial intermembrane space (Sturtz 
et al., 2001). The Plants have been reported to possess multiple forms of Cu,Zn-SOD 
located in the cytosol and chloroplast (Miller, 2001; Van Camp et al., 1990; Miller, 
2012) and also in the peroxisomes (Bueno et al., 1995), which are encoded by more 
than one gene. Animals have two different forms of Cu,Zn-SOD: dimeric 
cytoplasmic/intracelluar (McCord and Fridovich,1969) and tetrameric extracellular 
Cu,Zn-SOD (Antonyuk et al., 2009). The intracellular Cu,Zn-SOD has also been 
reported in the nuclei, lysosomes and peroxisomes (Chang et al., 1988). The 
extracellular Cu,Zn-SOD is distinct from the cytoplasmic one in terms of molecular 
mass well as the amino acid composition.  
1.1.2.2. Bovine Cu,Zn-SODs 
In 1982, the first complete three dimensional structure of Cu,Zn-SOD (Fig. 1) 
from the bovine erythrocytes was determined (Tainer et al., 1982). Later in 1992, the 
structure of human Cu,Zn-SOD was solved (Parge et al., 1992). It revealed that the 
human Cu,Zn-SOD shares high degree of sequence homology (83%), three 
dimensional structure, domain organization including amino acid sequence, protein 
fold and the catalytic properties with that of bovine erythrocyte enzyme (Bordo et al., 
1994; Didonato et al., 2003). The structure of the eukaryotic enzyme is found to be 
highly conserved (Perry et al., 2010).  
Bovine Cu,Zn-SOD is composed of two identical subunits and has a molecular 
mass of 32.0 kDa (Hough and Husnain, 1999). Both subunits are related to each other by 
an approximate 2-fold symmetrical axis along the dimeric interface (Hough and Husnain, 
1999). Extensive hydrophobic interactions and some hydrophilic contacts stabilize the 
dimer (Rae et al. 2001). Each subunit consists of a “greek key” eight stranded antiparallel 
β-barrel (Richardson, 1977) with three major external loops (Toyama et al., 2002) (Fig. 
2). The barrel contains 50% residues of the backbone (total 75 residues).  
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Fig. 1. Three dimensional structure of Cu,Zn-SOD. Cu,Zn-SOD is a dimer of two 
identical subunits each containing 150 amino acids. The enzyme active site contains a 
pair of Cu and Zn ions. 
 
 
 
 
 
 
 
 
 
Fig. 2. Subunit structure of bovine Cu,Zn-SOD. The atomic coordinates were taken 
from those of subunit B in the X-ray crystal structure of Cu,Zn-SOD (Protein Data 
Bank Entry 2SOD). The side chains are shown for the residues in the active site, on 
the rim of the active site pocket, and at an opening of β-barrel near His 41. For the 
hydrophobic residues losing off the β-barrel opening, transparent balls with vander 
walls radii are superimposed on the ball and stick model. The central hydrophobic 
plug Leu 38 is coloured yellow. Blue thin sticks represent hydrogen bonds, and brown 
plates represent amide planes (Toyama et al., 2004). 
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The core of the barrel is tightly packed by hydrophobic residues (Richardson 
et al., 1975; Perry et al., 2010). The main chains inside the barrel, are separated by 
12-13 Ȧ in the shorter direction and 16-17 Ȧ in longer direction. Another 
characteristic feature of the β-barrel is the presence of two halves. The first half, 
which is present towards the outside of the β-barrel, is very regular and less twisted. 
The second half is less regular and more twisted and is almost entirely internal to the 
subunit (Richardson et al., 1975). A section of this barrel and two of the loops, 
electrostatic loop and zinc binding site form the walls of the active site (Li et al., 
2010). Electrostatic loop contains several charged residues which provide an 
electrostatic guidance for enzyme substrate interaction (Polticelli et al., 1998; Ciriolo 
et al., 2001; Getzoff et al., 1992). The third loop provides a connection across the β-
sheet. The active site is found to be located in a shallow pit, some 10 Ȧ beneath the 
protein surface (Hough and Husnain, 1999). Each subunit contains one Cu and one Zn 
ion (Hough and Husnain, 1999). For the activity of the enzyme, active-site Cu ion is 
needed (DiDonato et al., 2003; Gotto et al., 2000), while both Cu and Zn ions 
contribute to the stability of the enzyme (DiDonato et al., 2003; Forman & Fridovich, 
1973; Abernethy et al., 1974). In each subunit, Cu and Zn sites are separated by about 
6 Ȧ, forming a dimetallic catalytic centre. The Cu ion has three coordinate positions 
in reduced form in both aqueous and crystalline slurry and it adopts a trigonal planar 
geometry and is ligated by three histidine residues (His 44, His 46 and His 118) 
(Blackburn et al., 1984). Cu ion is further found to be bridged with Zn ion by an 
anionic imidazole ring of another histidine residue (His 61) in its oxidized state. The 
Zn ion is ligated to one aspartic acid (Asp 81) and three histidines (His 61, His 69, His 
78) and has a distorted tetrahedral geometry (Richardson et al., 1975). There are eight 
histidine residues per subunit (Lippard et al., 1977). NMR structural analysis clearly 
indicates that Cu ion is exposed to the solvent and Zn ion is buried inside (Gaber et 
al., 1972; Cannio et al., 2000). The bovine Cu,Zn-SOD has a disulfide bond (Tainer et 
al., 1982; Getzoff et al.,1992) between the highly conserved pair of cysteines, namely 
Cys 55 and  Cys 144 (Abernethy et al., 1974). The binding of the active site metal 
ions and conserved disulfide bond in each subunit is considered to provide stability to 
the enzyme (Perry et al., 2010). 
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The generally accepted catalytic mechanism for dismutation of O2- by SOD 
involves two steps: cyclic Cu reduction and reoxidation (Hart et al., 1999). Two 
successive molecules of O2- are needed for this alternate reduction and oxidation of 
Cu ion. 
O2- + Cu(II),Zn-SOD                            O2 + Cu(I),Zn-SOD                              (1) 
O2- + Cu(I),Zn-SOD + 2H+                      H2O2 + Cu(II),Zn-SOD                             (2) 
The first step (equation 1) involves the reduction of Cu2+ and concominant Cu 
- Nε - His 61 bond protonation. The protonation results in the loss of Cu - His 61- Zn 
bridge on the Cu site.  However, a set of bovine Cu,Zn-SOD structures have been 
reported with an intact form of Cu-His61-Zn bridge (Banci et al., 1994; Rypniewski 
et al., 1995). Nevertheless, most of the data from solution studies strongly suggest the 
breakage of the imidazolate bridge.  Reduction of Cu2+ takes place by inner sphere 
mechanism, and Cu2+ accepts electron directly from O2-. A trigonal planar 
coordination geometry is adapted by the resulting Cu+ form (Bailey et al., 1980; 
Murphy et al., 1997; Hough and Hasnain, 2003). The product oxygen molecule easily 
diffuses out. The second step (equation 2) is suggested to proceed via outer sphere 
electron transfer from reduced Cu+ to O2-. The electron transfer is followed by 
reoxidation of Cu+, reformation of imidazolate bridge and release of H2O2 through 
proton donation from protonated His61. In both steps, O2- molecule is guided to the 
active site channel by a conserved set of charged amino acid residues (Getzoff et al., 
1989; Getzoff et al., 1992). The nucleus of this mechanism is the formation of a stable 
complex between Cu and O2- molecule. Cu,Zn-SOD shows high catalytic efficacy. 
Pulse radiolysis studies have revealed that the catalysis is diffusion controlled and pH 
independent (pH 5-9.5) & Kcat = K1= K2 ≈ 2×109 M−1 s−1 (Klug-Roth et al., 1973; 
Argese et al., 1987). 
Cu, Zn-SOD is highly thermal stable enzyme and its dismutation ability starts 
to decrease above 80oC with a melting temperature (Tm) of  90oC (Roe et al., 1988). 
The enzyme is quite resistant to denaturation by chemical treatment including 4% 
SDS and 10 M urea (Culotta et al., 2006). It is also resistant to physical treatments 
such as heating, freezing and freeze–thaw cycles, and also cleavage by proteinase K 
(Bafana et al., 2001). The enzyme is typically inhibited by azide, cyanide, 
diethyldithiocarbamate and H2O2, and is only gradually denatured in the presence of 6 
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M guanidine hydrochloride plus EDTA (Forman and Fridovich, 1973; Malinowski 
and Fridovich, 1979). The eight stranded antiparallel β-barrel, hydrophobic 
interactions associated with dimerization, co-ordinate/covalent bonds and an 
intrasubunit disulfide bond are considered to contribute to the remarkable stability of 
the enzyme (Hough and Hasnain, 2003; Perry et al., 2010). The hydrophobic β-barrel 
core and main-chain β-sheet hydrogen bonds contribute both to the structural integrity 
and folding of the enzyme (Perry et al., 2010). 
In order to become enzymatically active, Cu,Zn-SOD undergoes several post 
translational modifications including the acquisition of Cu and Zn ions, formation of 
the disulfide bond and dimerization (Culotta et al., 2006). The exact mechanism by 
which Cu,Zn-SOD acquires Zn2+ is not fully understood, there are some reports on the 
use of an accessory protein known as copper chaperone by the enzyme for facilitating 
the Cu insertion (O'Halloran and Culotta, 2000; Eisses et al., 2000). Most of the cells 
employ the copper chaperone for SOD (CCS) to deliver and incorporate the Cu ion 
into Cu,Zn-SOD. CCS is a soluble Cu carrier protein which docks with and transfers 
the metal ion to the disulfide-reduced apo Cu,Zn-SOD (Culotta et al., 1997).  
The key characteristics of SOD include its exceptional stability, speciﬁcity of 
fold and assembly which are due to conserved features within the “Greek-key” β-
barrel structure and dimer association as well as “cork” residues which stabilizes the 
ends of the β-barrel (DiDonato et al., 2003; Getzoff et al., 1989). 
1.1.3. Physiological significance of SOD 
SODs have great significance in the body as they catalyze the dismutation of 
O2- into H2O2 and oxygen molecule. The production of O2- occurs mostly within the 
mitochondria of the cell (Cadenas and Sies, 1998). The unchecked O2- may result in 
the formation of a cascade of deleterious ROS including H2O2, hypochlorite (OCl-), 
peroxynitrite (ONO2-) and hydroxyl radical (HO.) (Bryan et al., 2012). While low 
levels of ROS have beneficial effects, the high levels may initiate many lethal 
reactions including inactivation of enzymes, damaging/alteration effects in DNA, 
damage of proteins, lipids etc. DNA mutations may lead to genomic instability and 
tumorigenesis (Wiseman and Halliwell, 1996). There are various human disorders 
clinically associated with oxidative stress (Rahman et al., 2012). Therefore, SOD 
plays a critical role in protecting the organism against oxidative stress. 
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1.1.4. Therapeutic effects of SOD 
Several studies have been performed that reveal the therapeutic potential and 
physiological importance of SOD (Noor et al., 2002). The enzyme can serve as an 
anti-inflammatory agent and can also prevent precancerous cell changes (Yasui and 
Baba, 2006). Natural SOD levels in the body drop as the body ages (Inal et al., 2001) 
and hence as one ages, one becomes more prone to oxidative stress related diseases. 
SOD is used in cosmetics and personal care products as an anti-aging ingredient and 
antioxidant because of its ability to reduce free radical damage to the skin, therefore 
preventing wrinkles, fine lines and age spots, and it also helps with wound healing, 
softens scar tissue, protects against UV rays, and reduces other signs of aging  (Luisa 
Corvo et al., 2002). It has been reported that SOD has an important link in several 
human health problems including RBC related disorders, cystic fibrosis, 
postcholecystomy pain syndrome, malignant breast disease, steroid sensitive 
nephrotic syndrome, amyotrophic lateral sclerosis, etc., neuronal apoptosis, AIDS and 
cancer (Noor et al., 2002; Riley, 1999; Troy and Shelanski, 1994; Greenlund et al., 
1995; Riley, 1999; Bravard et al., 1992; Church et al., 1993; St. Clair et al., 1994; 
Riley, 1999). Furthermore, a strong association between the activity of SOD and 
Alzheimer’ disease has been suggested by some researchers (Noor et al., 2002). It has 
also been reported that treatment with SOD helps recovery from mustard gas burns 
(Eldad et al., 1998). In many animal models having myocardial ischemia-reperfusion 
injury, inflammation and cerebral ischemia reperfusion injury etc., SOD enzymes are 
found to be very effective (Salvemini and Riley, 2000). SOD mimics offer a potential 
for treating such diseases produced under conditions of oxidative stress (Riley, 1999). 
Several attempts have been made to use SOD as a therapeutic agent against the ROS 
mediated diseases.  
Many SOD mimetics have been synthesized that can be used as 
pharmaceutical agents in a large number of diseases in which native SOD is 
ineffective (Salvemini et al., 2002). Because of the instability, high immunogenicity 
and lesser circulation in vivo half-life of SOD, their clinical applications as 
therapeutic agent are very limited. To improve this pharmacological and biological 
problems, a wide variety of Cu,Zn-SOD conjugates have been developed with longer 
circulation half lifes, high stability and lesser immunogenicity (Ogino et al., 1988; 
Kakimoto et al., 1993). These SOD conjugates have exhibited marked effects in vivo. 
8 
 
1.1.4.1. SOD and cancer 
SOD, being a key cellular antioxidant, is highly responsible for the elimination 
of O2-. The inactivation and/or deficiency of SOD results in the irreversible cellular 
injury, which is mediated by accumulation of O2-. Many studies have revealed the 
critical role of oxidative stress in carcinogenesis (Wiseman and Halliwel, 1996; 
Monya et al., 2001). Indeed, there are several clear evidences indicating that ROS 
works as an endogenous class of carcinogens by inducing mutations in the cells 
(Guyton and Kensler, 1993; Feig et al., 1994; Gerutti, 1994). The diminished activity 
of Cu,Zn-SOD and Mn-SOD has been observed in cancer cells (Bafana et al., 2011; 
Oberley, 2004; St. Clair, 2014). Normalization of SOD level contributes to part of the 
cancer cell phenotype reversion (Bafana et al., 2011). It has been suggested that SOD 
may regulate cancer progression and hence, can be used as a novel target for cancer 
treatment (Papa et al., 2014a; Papa et al., 2014b; Tsang et al., 2014; Glasauer et al., 
2014). Furthermore, It has been shown that Cu,Zn-SOD can be used as a novel 
therapeutic target for the treatment of multiple myeloma (Salem et al., 2015). On the 
contrary, the invasive and migratory activity of pancreatic cancer is encouraged by 
SOD via activation of the H2O2/ERK/NF-κB axis (Li et al., 2015). 
1.1.4.2. SOD and inflammatory diseases 
Neutrophils play a central and essential role in the pathogenesis of 
inflammation. Activated neutrophils adhere to vascular endothelium and trans-migrate 
to the extravascular space, release ROS, protease enzymes, and large amounts of 
chemokines (Yasui and Baba, 2006). ROS and proteases damage normal tissue and 
extracellular matrix proteins. O2- serve to activate endothelial cells and enhance 
neutrophil infiltration (Salvemini et al., 1999; Masini et al., 2002). Studies performed 
in transgenic mice overexpressing extracellular SOD (Ghio et al., 2002) and SOD 
mimetic (Salvemini et al., 1999) have shown that inhibition of O2- can prevent the 
infiltration of neutrophils at the site of damage. Neutrophil apoptosis may also be 
important step in the resolution of inflammation. In individuals with down syndrome, 
neutrophil apoptosis increases and Cu,Zn-SOD is overexpressed (Yasui et al., 1999). 
Exogenous H2O2 together with SOD, increase the number of apoptotic neutrophils 
(Yasui et al., 2005). SOD may serve as an inhibitory agent of neutrophil mediated 
inflammation and may stand for a novel therapeutic approach for the ROS dependent 
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tissue damage induced by neutrophils via several mechanisms (Yasui and Baba, 
2006). Preclinical studies with bovine Cu,Zn-SOD showed encouraging results for its 
use as a human therapeutic agent in acute and chronic inflammatory conditions, 
including dermatosis due to burn and wound injury (Flohe, 1988; Niwa, 1989). 
Extracellular SOD, Mn-SOD and Cu,Zn-SOD have been described as potential 
inhibitor of inflammation by various reporters (Bowler et al., 2004; Joseph et al., 
2008). 
1.1.4.3. SOD and cystic fibrosis 
Cystic fibrosis (CF) is characterized by the chronic inflammation, and the 
recruitment of activated neutrophils (De Rose, 2002). In the plasma of patients with 
CF, SOD activity was significantly lower as compared with the healthy individuals 
(Madarsi et al., 2000). Also, in mononuclear, polymorphonuclear and red cells of 
CF patients, reduced Cu,Zn-SOD activity was observed (Percival et al., 1995). It has 
been found that the antifibrotic action of Cu,Zn-SOD is mediated by TGF-β1 
repression followed by phenotypic reversion of myofibroblasts (Vozenin-Brotons et 
al., 2001). Radiation-induced fibrosis of breast was significantly reduced by Cu,Zn-
SOD (Campana et al., 2004). These findings indicate new therapeutic possibilities 
targeting antioxidant pathways including SOD, so that oxidative stress and apoptosis 
can be reduced in CF cells, and proinflammatory response can be limited.  
1.1.4.4. SOD and ischemia 
ROS including O2- and its reaction product, peroxynitrite have a significant 
role in endothelial and tissue injury associated with ischemia and reperfusion. Over 
expression of Cu,Zn-SOD reduces ischemic damage resulting from 
ischemia/reperfusion (Yang et al., 1994). Mn-SOD targeted deletion deteriorates the 
outcome from both temporary and permanent middle cerebral artery occlusion (Kim 
et al., 2002; Murakami et al., 1998). The removal of O2- and peroxynitrite by SOD 
mimetic helps in the prevention of cellular energetic failure and tissue damage related 
with ischemia and perfusion and has a beneficial effect in this situation (Salvemini 
and Cuzzocreas, 2002). 
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1.1.4.5. SOD and aging 
SOD is considered to be an antiaging enzyme. The free radical theory of aging 
was proposed by Derham Harman (Harman, 1956). It postulated that oxygen free 
radicals generated in metabolic pathways, causes age related deterioration through 
oxidative damage to biomolecules with mitochondria being the main target of attack. 
Accumulation of oxidative damage is considered to be one of the key mechanisms of 
aging (Harman 1956; Hekimi and Guarente, 2003; Longo and Finch, 2003).  
Drosophila flies having 75% reduction in SOD activity, showed accelerated 
loss of olfactory behaviour upon ageing (Paul et al., 2007). The loss of SOD2 activity 
in Drosophila is highly related to the life span and age-related decline of olfactory 
system function. Studies on a series of Drosophila SOD2 mutants reveal the essential 
role of this gene in protecting flies from mitochondrial oxidative damage, 
neurodegeneration, age-related defects in behaviour and early-onset mortality (Paul et 
al., 2007).   
1.1.4.6. SOD and rheumatoid arthritis 
Rheumatoid arthritis is a systemic disease and is characterized by a chronic 
inflammation reaction in the synovium of joints leading to degeneration of cartilage 
and erosion of juxta-articular bone. ROS and other free radicals play an important role 
in the inflammation process and also damage cartilage and the extracellular matrix 
(Mahajan and Tandon, 2004; Hitchon and El-Gabalaway, 2004). Increased oxidative 
stress or deficient antioxidant status are critical in the pathogenesis of rheumatoid 
arthritis (Mahajan and Tandon, 2004; Hitchon and El-Gabalaway, 2004). Some 
antioxidants including SOD and vitamin E have an anti-inflammatory role in 
experimentally induced arthritis (Mahajan and Tandon, 2004). It was found that SOD 
activity is low in patients suffering from rheumatoid arthritis and the administration of 
SOD through liposomes had a positive effect in the treatment of experimental arthrits 
(Uger et al., 2004; Karatas et al., 2003). 
1.1.4.7. SOD and neurodegenerative diseases 
Oxidative stress has been shown to be involved in the pathophysiology of 
several neurodgenarative diseases. The affected regions of patients having Alzheimer 
disease have reduced activity of antioxidant enzymes such as SOD, catalase, 
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glutathione peroxidase and glutathione peroxidase (Zemlon et al., 1989; Papolla et al., 
1992). Familial amyotrophic sclerosis (FALS), is a fatal neurodegenerative disease that 
leads to the selective loss of motor neurons. Several mutations in Cu,Zn-SOD  gene are 
found to be associated with FALS (Cleveland and Rothstein, 2001). In addition, Cu,Zn-
SOD is one of the prime victim  of oxidative damage to the brain in Alzheimer 
disease and Parkinson disease (Choi et al., 2005).  
1.1.4.8. SOD and diabetes 
Increased oxidative stress plays a major role in the aetiology of diabetes 
and its complications (Baynes, 1991; Baynes and Thorpe, 1999; Ceriello, 2000). In 
diabetes, persistent hyperglycemia stimulates the production of ROS from various 
sources (Yan, 2014). As a result, diabetes usually leads to increased formation of 
ROS and weakened antioxidant defences (McLellan et al., 1994; Saxena et al., 
1993). The enhanced production and/or decreased removal of ROS by 
nonenzymatic and enzymatic antioxidant defences, increases the level of ROS in 
diabetic patients which damages many tissues, resulting in diabetic complications 
(Lipinski, 2001). 
Glyoxidation hypothesis states that glyoxidation plays a leading role in 
damage of long lived proteins during diabetes and aging (Baynes and Thorpe, 
1999). The α-ketoaldehyde formed from the auto-oxidation of glucose might 
significantly contribute to the commencement of nonenzymatic glycosylation of 
proteins (Wolff and Dean, 1987). Glucose auto-oxidation appears to be one of the 
main sources of free radicals during hyperglycemia (Ceriello, 2000). Enediol form 
of glucose is readily oxidized to enediol radical anion in a transition metal 
dependent reaction. Further, the enediol radical becomes converted into reactive 
ketoaldehydes and O2-. SOD catalyses the conversion of O2- into H2O2. If H2O2 is 
not degraded by catalase and peroxidase, it can lead to formation of highly reactive 
HO-. Moreover, reducing sugars such as glucose can also be oxidized and can form 
low molecular mass dicarbonyl compounds. These resultant dicarbonyl compounds 
are highly reactive and may react directly with the side chains of amino acid 
residues including both arginine and lysine and lead to the formation of a wide 
range of protein bound advanced glycation endproducts (AGEs) and crosslinks 
(Thorpe and Baynes, 2003).  
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Under hyperglycemic conditions, endothelial cells produce elevated levels of O2-
 (Graier et al., 1999). Overproduction of O2- can inhibit glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) which is an important enzyme of the glycolytic pathway (Du et 
al., 2003). This leads to the accumulation of glucose and other intermediate metabolites 
of this pathway and shifts to other alternative pathways of glucose metabolism along with 
increased production of AGEs. The enormous amount of O2- causes the state of oxidative 
stress, which in turn causes the impaired antioxidant defense, increased glucose auto-
oxidation and protein glycoxidation (Baynes, 1991). The oxidation reaction of both free 
and protein-bound sugars mediated by radicals, is termed as glycoxidation (Pennathur and 
Heinecke, 2004). Protein glycoxidation indicates the underlying-chemical modification 
and crosslinking of tissue protein that is induced by reducing sugars and glycoxidation 
products can be regarded as the biomarkers of carbohydrate dependent damage of 
proteins (Baynes, 1991).  
Lipid peroxidation of low density lipoproteins is also found to be promoted 
by hyperglycemia (Jain, 1989). Glycation or non-enzymatic glycosylation of proteins 
is also a source of free radicals in diabetes, contributing to diabetic complications 
(McCance et al., 1993). Further, increased oxidative stress is found to be associated 
with diabetic complications (Kangralkar et al., 2010; Ceriello, 2000). 
1.2. Glycation or non-enzymatic glycosylation of proteins 
Glycation or Maillard reaction is a spontaneous, naturally occurring, non-enzymatic and 
complex network of reactions which is initiated by reaction of carbonyl group of a 
reducing sugar (e.g., glucose, galactose, fructose, mannose or ribose) with a free amino 
group, typically the ε-amino group of lysine residues and the α-amino group at the N-
terminus of a protein to form an adduct commonly referred to as the Schiff base (Zhang 
et al., 2009) (Fig. 3). The Schiff bases undergo Amadori rearrangement and through a 
series of further rearrangement, cyclizations etc. form a variety of diverse compounds 
collectively described as AGEs (Neglia et al., 1983; Baynes et al., 1989). AGE 
formation is accompanied by the formation by the formation, among others of a number 
of ROS, α-oxoaldehydes, that further react and damage the proteins and other important 
biological molecules. Glycation plays an important role in the development of 
physiological and pathophysiological processes such as aging, diabetes, atherosclerosis, 
neurodegenerative diseases and chronic renal failure (Brownlee, 1995).  
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Fig. 3. Glycation of proteins. The initial reaction between glucose and protein amino 
groups forms a reversible Schiff base that rearranges to a ketoamine or Amadori 
product. With time, these Amadori products form AGEs via dicarbonyl intermediates. 
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The Maillard reaction was first observed by Louis-Camille Maillard in 1912 
(Maillard, 1912). Upto 1980’s, most of the work on glycation was done for the food 
science field and related to the flavour, colour and nutritional value of food. 
Nowadays, pathophysiological impacts of the Maillard reaction on the human health 
are more of concern in relation to the diabetic complications, and age related diseases 
such as atherosclerosis, Alzheimer’s disease and inflammation (Basta et al., 2002; 
Baynes and Thorpe., 1999; Munch et al., 1998). In the physiological systems, 
cellular and extracellular proteins are spontaneously damaged by glycation 
(Thornalley, 1999; Thornalley et al., 2003). Due to glycation, not only the structural 
properties such as charge, solvation and/or conformation of proteins, but also the 
biological properties are affected (Fig. 4). Therefore, glycation can also change the 
functional properties of proteins (Darewiczb and Dziuba, 2001; Khan et al., 1999; 
Morgan et al., 1999; Nakamura et al., 1994). The resulting protein modification can 
possibly explain the reason for the tissue damage that occurs in persistent 
hyperglycemic conditions (Dyer, 1993; McCance et al., 1993). Furthermore, 
glycation can induce structural changes in enzymes that include conformational 
alterations, thio-oxidation, aggregation, formation of disulphide and other cross 
links, and inactivation of enzymes (Harding, 1991). Previous studies have reported 
that glycation causes the alteration in the activity of some enzymes such as SOD 
(Arai et al., 1987a; Arai et al., 1987b), carbonic anhydrase (Kondo et al., 1987), 
alcohol dehydrogenase (Shilton and Walton, 1991), aldehyde reductase (Takashaki et 
al., 1995), etc. Although, a number of free amino groups are present on the surface of 
proteins, only a few are selected for glycation. Only those amino groups are selected 
for glycation that are either adjacent to an imidazole moiety or are a part of a lysine 
doublet. If an amino acid is very close (approximately 5Å) to an imidazole group, it 
will be highly susceptible to glycation (Bunn et al., 1976). The degree of glycation of 
a protein depends on a number of independently acting factors such as pH, 
temperature, protein concentration, etc. (Brownlee et al., 1984, Eble et al., 1983). In 
addition, it is highly affected by the glucose concentration as well as the incubation 
period, which are both clinically more relevant factors (Brownlee et al., 1984). The 
rate of glycation in vivo depends on the sugar concentration, reactivity of the free 
amino groups of the biomolecules and their half-life (Nawale et al., 2006). 
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Fig. 4. Effect of glycation on proteins and AGE formation. A nonenzymatic 
reaction between glucose or other reducing sugar and the N-terminal amino acid 
residues and/or ε-amino groups of proteins initially forms a Schiff base adduct. The 
Schiff base adduct then slowly undergoes Amadori rearrangement. Additional 
dehydration, condensation, fragmentation, rearrangement, and oxidation results in the 
formation of AGE (Kikuchi et al., 2002). 
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1.2.1. Chemistry of glycation  
Glycation is a non-enzymatic covalent interaction between reducing sugars 
and either ε-amino group of lysine residues or α-amino group present at the N-
terminal groups of a protein. It is an example of neucleophilic addition reaction 
(Dyer, 1993; Forbes et al., 2003; McCance et al., 1993; Price et al., 2001; Ulrich and 
Cerami, 2001). It can be divided into three prime steps: early, intermediate and late. In 
the early stage, glucose or other reducing sugars react with the nucleophilic groups of 
proteins, lipids, and nucleic acids and form Schiff base as the intermediate products 
(Ahmed, 2005; Brownlee et al., 1984). Formation of Schiff base is relatively very fast 
and highly reversible. Schiff bases are highly unstable and are reversible aldimine 
compounds (Brownlee et al., 1984; Ulrich and Cerami, 2001). Depending on the 
surrounding glucose concentration, Schiff base rapidly reaches an equilibrium level in 
vivo. After several rearrangements, Schiff base leads to the formation of a stable yet 
reversible ketoamine or Amadori products. The rate of production of Amadori 
products is dependent on the concentration of glucose (Brownlee, 1995). They 
become accumulated on both short lived as well as long lived proteins (Thornalley, 
1996). During the formation of AGEs, Amadori products are intermediate reaction 
products (Brownlee et al., 1984; Baynes et al., 1999; Ahmed, 2005; Ulrich and 
Cerami, 2001).  
In the intermediate stage, the degradation of Amadori products leads to 
formation of a number of carbonyl compounds, such as glyoxal, methylglyoxal (MG) 
and deoxyglucosones that may work as propagators of the reaction (Thornalley et al., 
1999; Glomb and Monnier, 1995). Amadori products can undergo several 
transformations through numerous divergent pathways. These pathways can involve 
oxidation, fragmentation, enolization, dehydration, acid hydrolysis and free radical 
reactions, and result in the formation of a large variety of poorly characterized 
compounds (Friedman, 1996). In the late or final step, the propagators further react 
with free amino groups and form AGEs after undergoing various reactions including 
irreversible oxidation, dehydration and cyclization etc. AGEs are yellow-brown 
heterogeneous compounds with an ability to form covalent bonds with the amino 
groups of other proteins and thus cause protein cross-linking (Eble et al., 1983). They 
can disturb several physiological functions because of their ability to form insoluble 
aggregates. AGEs are considered to be relatively indigestible. However, AGEs may 
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be taken up to lysosomes via some specific cell-surface binding sites, the receptors for 
AGE (RAGE), as well as macrophage scavenger receptor, where they are degraded 
out into small AGE peptides or fragments (Vlassara et al., 1994). The resultant 
fragments can contain irregular components of parental AGE moieties (Vlassara et 
al., 1994).  
1.2.2. Pathogenicity of AGEs and glycation 
In vivo AGEs accumulate in the plasma (Makita et al., 1995), vascular tissues 
(Aronson, 2002), the kidney (Heidland et al., 2001) and on arterial wall (Brownlee et 
al., 1986). AGEs are supposed to be involved in the pathogenesis of age-related 
disorders that can affect connective tissue, lens, blood vessels, and nerves (Brownlee, 
1995). Previously, it was thought that only long lived extracellular proteins 
accumulate AGEs, however it is now known that they can be formed on short-lived 
molecules and even intracellular growth factors (Giardino et al., 1994). Extracellular 
proteins are more likely to be influenced by AGE modification because of slow turn-
over rate (Goh and Cooper, 2008). Glycation leads to intra-molecular as well as inter-
molecular crosslinking with collagen. Crosslinking brings about several structural 
alterations which result in the increased stiffness as well as resistance to proteolytic 
digestion (Goh and Cooper, 2008). These processes are increased in the persons 
suffering from diabetes. AGEs continuously accumulate over the lifetime of the 
protein and do not return back to their normal when hyperglycemia is corrected. It is 
suggested that even a moderate elevation in blood glucose level can result in a 
substantial increase in AGE accumulation (Ahmed, 2005). The major AGEs (Fig. 5) 
in vivo appear to be produced from highly reactive intermediate carbonyl groups, 
known as α-dicarbonyls or oxoaldehydes, including 3-deoxyglucosone, glyoxal, and 
MG (Brownlee, 2001; Thornalley, 1996). The rate of intracellular AGE formation is 
faster as compared to that in the extracellular compartment (Monnier, 1989) because 
the rate of glycosylation product formation is found to be slowest for glucose as 
compared to all naturally existing sugars (Brownlee, 1995). Glycation in vivo along 
with AGEs accumulation has been found to be implicated in the pathogenesis of 
several chronic diseases including typical diabetic complications, atherosclerosis, 
Alzheimer’s disease, rheumatoid arthritis and chronic heart failure (Smit et al., 2008; 
Meerwaldt et al., 2008; Smit and Lutgers, 2004; Vlassara and Palace, 2002).  
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Fig. 5. Chemical structures of various major protein AGEs detected in tissue 
proteins. (Thorpe and Brown, 2003). 
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Increased glycation and build-up of tissue AGEs can alter enzymatic activity, 
decrease ligand binding, modify protein half-life and alter immunogenicity, so they 
have been considered to be a major factor contributing to diabetic complications 
(Vlassara and Palace, 2002). Furthermore, increased free radical production during 
protein glycation and AGE formation is also a major cause of biomolecular damage in 
diabetic conditions (Ahmed, 2005; Wautier and Guillausseau, 2001). Atherogenesis in 
diabetic patients is caused by AGE-immune complexes formed from autoantibodies 
and their corresponding serum AGEs (Turk et al., 2001). Several AGEs are more 
chemically reactive and are termed as glycotoxins (Vlassara et al., 1994). During 
diabetes and ageing, one of very common symptoms is the rigidity as well as 
thickening of capillary walls, which is caused by cross-linking of collagen proteins by 
AGEs (Nawale et al., 2006).  
Free radicals formed during glycation, can lead to protein fragmentation and 
oxidation of nucleic acids and lipids (Baynes, 1991). Moreover, glycation cytotoxicity 
can be a result of production of ROS, inhibition of specific functions of proteins, cross 
linking, aggregation, and precipitation of proteins. Reduced enzymatic activities of 
Cu,Zn-SOD and other antioxidant enzymes have been reported to occur in the kidney, 
heart tissue as well as the liver of diabetic patients, while the levels of ROS including 
O2- are increased (Asayama et al., 1989; Giugliano,1995).  
The pathogenic effects of AGEs are exerted either directly or by interaction 
with some specific receptors e.g. RAGE. RAGE is found on smooth muscle cells, 
macrophages, endothelial cells and astrocytes (Ahmed, 2005). RAGEs are very 
crucial as their interaction with AGEs induces the activation of secondary messenger 
pathways such as protein kinase C. The binding of ligand with RAGE triggers the 
activation of the NF-κB and other signalling pathways via the stimulation of 
extracellular signal-regulated kinase-1/2 (ERK), p38 MAPK (mitogen-activated-
protein-kinase), the stress-activated protein kinase/c-jun Nterminal kinase 
(SAPK/JNK) kinases, rho-GTPases, phosphoinositide 3-kinases, JAK/STAT (Janus 
kinase/signal transducer and activator of transcription) pathway and Rac-Cdc42 
(Bopp et al., 2008).  Several of them are the results as well as the cause of ROS 
(Thornalley, 1998; Hori et al., 1995; Sorci et al., 2004; Taguchi et al., 2000; Huang et 
al., 2001; Ishihara et al., 2003). During inflammation and diabetes, RAGE is highly 
expressed. Some researchers have found that pharmacological blockade of RAGE 
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in db/db diabetic mice provides protection against glomerulosclerosis and early 
diabetic nephropathy (Wendt et al., 2003). Deletion of the RAGE gene protects 
animals from the adverse effects of diabetes, while over expression of RAGE supports 
diabetic neuropathy (Toth et al., 2008; Vincent et al., 2007). Therefore, RAGE has a 
considerable role in diabetic nephropathy. 
1.2.3. Dicarbonyls formed during glycation 
Prolonged hyperglycemia exerts many detrimental effects and may be the key 
cause of most diabetic complications. Because of hyperglycemia, numerous 
dicarbonyl compounds become accumulated that lead to carbonyl stress. Dicarbonyls, 
in general, can be produced as glycolytic intermediates during glucose metabolism 
and as secondary intermediate products produced during Maillard reaction by 
degradation of glycated proteins as well as during the lipid peroxidation of 
polyunsaturated fats (Turk, 2010). Moreover, the sugar moiety, itself can lead to 
formation of several low molecular weight dicarbonyl compounds such as MG, 
glyoxal, glycoaldehyde, 3-deoxyglucosone (3-DG), etc (Fig. 6 and Fig. 7). The 
plasma from diabetic patients has high level of these dicarbonyls (Han et al., 2007). 
The dicarbonyl compounds are even more reactive than their parent sugars and act as 
key components of carbonyl stress (Thorpe et al., 2000). They are characterized by 
remarkable high chemical reactivity and are able to form AGE-structures even at very 
low concentration. They have been suggested to have a role in the carbonyl stress 
reactions leading to hasten vascular damage in diabetes (Thorpe et al., 2000).  
MG or pyruvaldehyde is a highly reactive electrophilic α-oxaldehyde or 
dicarbonyl compound (Thornalley, 1996; Kalapos, 1999) and is generated through 
both enzymatic as well as non-enzymatic pathways intracellularly. Glyoxalase checks 
its interactions with body protein and nucleic acids (Thornalley, 1999) and converts                 
it into the inert product D-lactate (Thornalley, 1994a; Thornalley, 1994b). MG                     
is produced either from the fragmentation of an ene-diol triose phosphate glycolytic 
intermediates [dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-
phosphate] or by the spontaneous elimination of a phosphate group                                  
from glyceraldehyde-3-phosphate and DHAP (Thornalley, 1999). Rate of MG 
formation becomes high during diabetes and especially in the cells having high 
amount of accumulated glucose during hyperglycemia (Turk, 2010; Brownlee, 2001).  
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Fig. 6. Structures of some intermediate dicarbonyls formed during glycation. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Mechanistic interpretation of glyoxal, methylglyoxal and 3-deoxyglucosone 
formation in early glycation. RNH2 represents lysyl side chain and N-terminal amino 
groups (Thornalley et al., 1999). 
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MG synthase is believed to be involved in the conversion of DHAP into MG, 
especially when the supply of inorganic phosphate is inadequate (Hopper and Cooper, 
1971). In addition, MG is also formed from ketone body metabolism, oxidation of 
acetoacetate, oxidation of acetoacetate in neutrophils catalyzed by myeloperoxidase 
and catabolism of threonine via aminoacetone in diabetic ketoacidosis (Thornalley, 
1999; Lyle and Singh, 1992). 
MG is a more potent glycating agent as compared to because the specific 
reactivity of MG is 20,000-fold higher than that of glucose (Rabbani and Thornalley, 
2014). The concentration of MG in plasma is approximately 50,000-fold lower than 
that of glucose because glyoxalase enzyme is efficiently able to detoxify MG in vivo 
(Rabbani and Thornalley, 2014). Diabetes and other metabolic disorders can increase 
the rate of formation of MG (Nagaraj et al., 1996). As a consequence, the 
concentrations of MG and MG-derived AGEs are found to be increased in tissues 
(Ahmed, 1997). There can also be another cause for arise in MG level such as 
decreased clearance of MG by the detoxification pathways. MG plays an important 
role in oxidative stress (Desai et al., 2008). Several studies have indicated that MG 
increases the production of O2- (Chang et al., 2005; Ho et al., 2007), H2O2 and 
ONO2- (Chang et al., 2005; Dhar et al., 2008; Ward et al., 2004), proinflammatory 
cytokines such as interleufkin 1 (IL-1) (Di Loreto et al., 2004), IL-6 and IL-8 
(Wang et al., 2007; Di Loreto et al., 2004). 
Carboxyethyl lysine (CEL) and MG lysine dimer (MOLD) are generated 
when MG reacts with lysine residues of proteins (Bourajjaj et al., 2003). However, 
being an arginine-directed glycating agent, MG mainly forms a hydroimidazolone 
adduct, MG-H1 (Rabbani and Thornalley, 2012). Therefore, proteins are more like to 
be functionally altered by MG glycation because their functional domains have 
higher number of arginine than lysine residues (Thornalley and Rabbani, 2011). 
Besides, MG reacts rapidly with functional groups of proteins such as guanidino and 
thiol groups, and leads to browning and crosslinking of proteins as well as formation 
of fluorescent products, and it ultimately can cause denaturation of proteins 
(McLaughlin et al., 1980; Lo et al., 1994). Both, cellular and extracellular proteins 
can be glycated by MG because a minor fraction of intracellularly formed MG leaks 
out and bring about the glycation of extracellular proteins (Karachalias et al., 
2010).3-DG, a small aliphatic aldehyde with a low molecular mass and it takes part 
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in the formation of adducts with proteins. The production of 3-DG in humans occurs 
either during the intermediate steps of Maillard reaction or from fructose-3-
phosphate through the polyol pathway (Turk, 2010). Studies have shown the 
presence of 3-DG in the lens and heart of diabetic rats, and elevated level of 3-DG 
occurs in the erythrocytes of haemodialysis patients (Lal et al., 1997; Tsukushi et al., 
1999). Several 3-DG related AGEs such as caboxymethyl lysine (CML), 3-DG-
imidazole, pyrraline and a minor product “pentosidine” are produced only when 3-
DG reacts with the amino groups of proteins (Jono et al., 2004). 3-DG-imidazolone 
is a dominant product of 3-DG derivatived AGEs (Ahmed et al., 2005; Jono et al., 
2004). Like MG, 3-DG has the ability to inactivate glutathione reductase that 
accelerates oxidative damage (Turk, 2010). 3-DG also disrupts the glucose 
metabolism as it inhibits the activities of hepatic enzymes (Turk, 2010). The uremic 
and diabetic patients have elevated plasma levels of 3-DG (Niwa et al., 1995; 
Hamada et al., 1997). 3-DG-imidazolone and CML can induce modifications in 
cytokines and growth factors (Turk, 2010). Therefore, they are believed to contribute 
to the pathology of diabetic vascular diseases. 
Glyoxal is also an intermediate product of Maillard reaction. Additionally, it is 
also a by-product of the lipid peroxidation (Turk, 2010). It is a significant precursor of 
AGEs and has an importance as a glycating agent in physiological systems. Glyoxal-
lysine dimer (GOLD) is a lysine-lysine cross linking structure and is a specific 
glyoxal-derived AGE (Turk, 2010). In diabetic state and aged human beings, the level 
of GOLD is elevated (Frye et al., 1998; Shamsi and Nagaraj, 1999; Sady et al., 2000). 
There is a significant increase of plasma glyoxal level in diabetic patients (Lapolla et 
al., 2003; Han et al., 2007). CEL and its homologue CML is formed by the reaction of 
MG and glyoxal with proteins, respectively (Ahmed et al., 1997). Therefore, 
oxidative stress can be indicated by excess amount of MG, CEL and CML in tissues 
(Baynes and Thorpe, 1999; Vlassara et al., 1994; Ando et al., 1999; Li et al., 1996; 
Sugimoto et al., 1997). Therefore, there is a significant role of dicarbonyl compounds 
and oxidative stress in the chemical modification of proteins in aging and disease 
(Ahmed et al., 1997). 
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1.2.3.1. Metabolism of dicarbonyl compounds 
The glyoxylase system is an important metabolic pathway and is found in the cytosol 
of cells and cellular organelles, particularly mitochondria. It is present in all forms of 
life (Carrington and Douglas, 1986). The glyoxalase system catalyzes the conversion 
of MG and glyoxal into D-lactate and glycolate, respectively (Thoranalley, 2003). 
Two enzymes, glyoxalase I and glyoxalase II complete this catalytic reaction and they 
work in a sequential manner. Reduced glutathione (GSH) is required for the activity 
of both enzymes (Carrington and Douglas, 1986).  
The reactions are: 
 
RCOCHO    +   GSH                                RCOCH(OH)-SG 
(MG/Glyoxal)                                           Hemithioacetal 
                          
                                                                                 Glyoxalase I 
 
         MeCH(OH)CO-SG 
 
                                                                (S-2-hydroxyglutathione)  
 
 
                                               Glyoxalase II 
RCH(OH)CO-SG  +  H2O                               RCH(OH)COOH + GSH 
Detoxification of 3-DG results in the formation of 3-deoxyfructose and is catalysed by 
NADPH dependent aldehyde reductase and aldose reductase (Feather, 1995).  
 
                  3-DG reductase 
    RCOCHO           RCOCH2OH 
3-Deoxyglucasone                                3-Deoxyfructose 
 
The oxidation of 3-DG to 3-deoxygluconate is catalyzed by 2-oxoaldehyde 
dehydrogenase (Fujji et al., 1995) 
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1.2.4. Prevention of glycation 
Controlling blood sugar level is a very effective and natural method to 
prevent excessive glycation in diabetes. Basically, glycation can be prevented by 
natural defence system present inside the body or by inhibitors that may be synthetic 
or natural. 
1.2.4.1. Natural defence 
Several researchers have proposed the concept of an enzymatic defense 
against glycation that offers protection against cell damage mediated by glycation. 
This concept is based on the enzymatic activities that involves the 
prevention/suppression of glycation adducts formation and catalysis of glycated 
protein repairing. Glyoxalase system (both I and II), aldehyde reductase, aldose 
reductase and the liver enzyme, α-ketogluteraldehyde dehydrogenase are considered 
to be included in these natural enzymatic defence mechanisms against glycation and 
AGEs accumulation (Thornalley, 1990; Thornalley, 1998). Amadoriosis, an exclusive 
enzyme found in Aspergillus, catalyzes the deglycation of Amadori products 
(Gerhardinger et al., 1995). Human fructosamine-3-kinase (FN3K) is able to reverse 
the non-enzymatic glycation at an early stage (Szwergold et al., 2001). Reactive 
dicarbonyl compounds are detoxified by oxaldehyde dehydrogenase and aldehyde 
reductase that are NADPH dependent (Boel et al., 1995; Suzuki et al., 1998). During 
the reduction of peroxide or superoxide, gluthathione (GSH) system work both as 
antioxidant and coenzyme. Furthermore, GSH has an important role to facilitate the 
detoxification of MG in glyoxylase pathway (Thornalley, 1998). Numerous plasma 
amines are present in body that may react with sugar and Amadori carbonyl groups to 
decrease AGEs. Extracellular ligand-binding domain of the receptor or soluble RAGE 
can be used to block RAGE and this is shown to enhance wound closure in 
genetically diabetic mice (Goova et al., 2001).  
1.2.4.2. Antiglycating compounds  
Several types of antiglycating agents have been described (Taha et al., 2014). 
These can interefere with different potential sites to inhibit glycation and AGE 
formation (Fig. 8). Some may have the ability to compete for the amino groups  on          
the protein (Harding and Ganea, 2006; Brownsen and Hipkiss, 2000). Other can  
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Fig. 8. Potential sites where pharmacological compounds can act to inhibit 
protein glycation and AGE-mediated damage (Ahmed et al., 2005). 
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directly bind to the protein or can bind the glycation intermediates to stop the 
progression up to AGE formation stage (Harding and Ganea, 2006). Otherwise, they 
may have the property to eliminate the open chain form of glycating sugars (Harding 
and Ganea, 2006). Furthermore, several probable AGE inhibitors have been proposed 
(Rahbar and Figarola, 2003; Rahbar et al., 2000). Various inhibitors have been 
developed and some of them are in advanced clinical studies/trials (Williams, 2004; 
Giannoukakis, 2005; Thomas et al., 2005). The concept of inhibitory mechanism is 
primarily concentrated on blocking of the sugar attachment to proteins, attenuating 
glycooxidation and oxidative stress through trapping or scavenging some glycation 
intermediates including ROS, reactive nitrogen species (RNS) and dicarbonyls as 
well as breakage of AGEs crosslinks (Reddy and Beyaz, 2006).  
Primarily, inhibitors can be divided into two groups: synthetic and natural inhibitors.  
1.2.4.2.1. Synthetic inhibitors  
(1) Inhibitors interfering with sugar attachment with proteins 
 It has been found that only a few of the synthetic inhibitors have the property 
to interfere with the initial attachment of reducing sugars to the amino groups of 
proteins. For example, aspirin inhibits the glycation process by acetylating free amino 
groups of proteins therefore it can block the attachment of reducing sugars with amino 
groups (Crompton et al., 1985; Rao et al., 1985). An anti-inflammatory drug, 
diclofenac can make a covalent interaction with proteins and thus, can block the 
attachment of sugars with proteins. It has been shown to block at least one of the 
major glycation site of human serum albumin (Van-Boekel et al., 1992). Inositol is a 
synthetic and potent antiglycating agent because glucose can be scavenged out by 
inositol, and it was found that the glycation process decreased by 57-67 % in human 
eye lens protein in the presence of inositol (Ramakrishnan et al., 1999). Arginine and 
arginine-lysine can prevent the alterations of rat tail tendon that are induced by 
glycation because of competitive attachment of these amino acids to glucose (Mendez 
and Leal, 2004). Metformin is a well-known blood sugar lowering agent and has been 
reported to have moderate inhibitory effects on early stage of glycation (Rahbar               
and Figarola, 2003). Pioglitazone and pentoxifylline are other synthetic drugs                 
that exert the same inhibitory effect on early stage of glycation (Rahbar et al., 2000). 
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(2) Inhibitors inhibiting the late stage of glycation 
 Some synthetic inhibitors have the ability to scavenge both reactive carbonyls 
and reactive free radicals formed during glycation or can block the formation of 
Amadori products. Aminoguanidine (AG) and pyridoxamine are potent carbonyl and 
free radical scavengers and have been widely studied to investigate their AGE 
inhibiting property. AG was the first AGE inhibitor to be studied both in vitro and in 
vivo (Brownlee et al., 1986). AG has a significant potential to react with dicarbonyl 
intermediates formed during glycation (Brownlee, 1986; Corbett et al., 1992). Thus, 
AG helps in prevention of progression of diabetic complications (Thornalley, 2003). 
Previous studies have provided the evidences that AG is not only a potent AGE 
inhibitor, but also works in prevention of diabetic complications that include 
nephropathy, neuropathy and vasculopathy (Thornalley, 2003). Pyridoxamine and 
thiamine pyrophosphate are potential dicarbonyl scavenger and have a strong 
inhibitory effect on AGE formation. Pyridoxamine offers more protection against 
AGE formation (Metz et al., 2003; Voziyan et al., 2002; Khalifah et al., 1999) as 
compared to AG (Booth et al., 1996) by trapping dicarbonyl compounds (Ahmed et 
al., 2005; Voziyan et al., 2002). Thiamine pyrophosphate has also comparable 
inhibitory effect on AGEs formation (Booth et al., 1997). 
  Buformin (Kiho et al., 2005) and carnosine (Hipkiss et al., 1994; Yan and 
Harding, 2005) can prevent in vitro protein glycation and cross linking. 
(3) Inhibitors with radical scavenging properties 
 Some compounds are reported to retard or suppress AGE formation because of 
their possible radical scavenging properties. Calcium antagonists (Sobal et al., 2001), 
amlodipine (Akira et al., 2006), kinetin (Verbeke et al., 2000) and quinine (Jung et 
al., 2005) are able to retard or supress AGE formation possibly due to radical 
scavenging abilities. 
(4) Inhibitors with property to inhibit Amadori product formation 
Some antiglycating compounds have the ability to inhibit the formation of 
Amadori products. Tenilsetam is able to attach with sugar-derived moieties of 
glycated proteins (Munch et al., 1994). Thus, reactive sites are blocked and this 
stops the further polymerization reactions. Some researchers have also 
29 
 
reported the inhibition of formation of Amadori products and reduction in the 
level of AGEs by pencillamine (Stevens, 1995). Ethanol can be metabolized 
into acetaldehyde in vivo which forms a stable complex with Amadori 
products, thus ethanol may exert inhibitory effect on AGE formation (Al-
Abed et al., 1999). 
(5) Cross-link breakers 
 Cross-linking between AGEs and proteins is the reason behind the stiffening 
of arteries and cardiovascular damages (Zieman et al., 2005). Hence, breakage of 
AGE cross-links is a very good method to prevent diabetic complications caused by 
cross-linking. The concept of AGE breakers suggests that they can release albumin 
from preformed AGE-albumin-collagen complexes and can be able to dissociate the 
immunoglobulin adducts from red cells of diabetic rats (Nagai et al., 2012). Another 
view implicates the involvement of AGE breakers in the prevention of cross-linking 
and/or reversing of the cross-links once they are formed (Nagai et al., 2012; Susic, 
2007). One more way by which AGE breakers can work is metal chelation (Price et 
al., 2001).  
N-phenacylthiazolium bromide (PTB) was the first cross-link breaker 
reported (Vasan et al., 1996). Alagebrium (ALT-711) is a small synthetic compound 
and is able to decrease cardiovascular stiffening (Asif et al., 2000) and drug retarded 
nephropathy (Forbes et al., 2003) in diabetic rats. Furthermore, TRC4186 is a 
pyridinium analogs that are able to break AGE cross-links (Chandra et al., 2009). 
(6) Other miscellaneous synthetic inhibitors 
Some anti-inflammatory drugs including acetylsalicylic acid, ibuprofen, 
indomethacin and diclofenac act as antiglycating agents because they inhibit 
oxidative stress (Shastri et al., 1998; Caballero et al., 2000). Specific iron chelators 
like desferoxamine was also helpful in treating diabetes (Liu et al., 2009). Aldose 
reductase inhibitors (ARIs) can block excessive glucose metabolism. Eplarestat is an 
ARI and it brings about the lowering of the level of fructose-3-phosphate in diabetic 
patients (Hamada et al., 1995) and also lowers down imidazolone and CML (AGEs) 
due to decreased peroxidation of lipids (Tsukushi et al., 1999). 
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Angiotensin II Receptor Blocker (ARB) and Angiotensin converting Enzyme 
Inhibitors (ACEI) also have inhibitory effects on AGEs. The possible mechanisms of 
action may include chelating of metal ions, scavenging of free radicals, trapping of 
carbonyl compounds and/or inhibition of carbonyl compound production (Miyata et 
al., 2002).  
1.2.4.2.2. Natural inhibitors 
Although synthetic compounds are strong antiglycating agent or strong 
inhibitors of AGE formation, they might exert severe adverse effects. For example, 
the clinical trials of AG were terminated because of safety concerns because AG was 
found to have many adverse effects like gastrointestinal disturbances, rare vasculitis, 
anaemia and flu-like symptoms (Freedman et al. 1999). Its interference with vitamin 
B6 metabolism is another major limitation (Miyata et al., 2002). Metformin, another 
synthetic antiglycating compound exerts several adverse effects including nausea and 
diarrhoea (Kavishankar et al., 2011). Therefore, recently much interest has been 
developed in the search of natural phytochemicals from plants that effectively inhibit 
glycation and have fewer side effects (Coman et al., 2012). Naturally occurring 
phytochemicals/products have been found to be relatively safe for human 
consumption as compared to synthetic compounds and are relatively non-toxic, 
inexpensive and are available in an ingestible form. A large number of plants and 
natural biomolecules have been discussed in literature for their antidiabetic effects 
(Coman et al., 2012; Bailey and Day, 1989; Soumyanath, 2006). Some plant extracts, 
fractions and compounds have been tested for antiglycating activities (Pang et al., 
2011) However, the mechanism is often not completely understood. 
It is well established that glycation and AGEs formation are accompanied and 
accelerated by oxidative stress, therefore antioxidant compounds may be promising 
agents for the prevention of glycation and AGE formation. Polyphenolic compounds 
especially flavonoids have received most attention with regard to their antidiabetic 
properties (Soumyanath, 2006). Anthocyanins are flavonoids with high antioxidant 
capacity. Many plants have been used by the local Indian tribes for antidiabetic 
therapeutics since a long time, but only a few of them have been scientifically 
studied e.g. Flemingia macrophylla, Potentilla fulgens L., Albizzia lebbek, Curcuma 
amada, Gymnoptela cochinchinesis and Ixeris gracilis DC (Syiem and Warjri, 2011). 
31 
 
Methylcaffeate from Solanum torvum is found to have a hypoglycemic effect 
(Gandhi et al., 2011). Aqueous/ethanolic extracts of Allium cepa (skin), Illicium 
religiosum (bark and wood), Fagopyrum esculentum (hull), Origanum officinalis 
(leaf) are proved to have effective antiglycating and antioxidant properties (Kim and 
Kim, 2003). The results also showed that their antiglycating activities significantly 
correspond to their antioxidative capacities (Kim and Kim, 2003). Aged garlic 
extract is a potential inhibitor of AGEs with potent antioxidant activities (Ahmad and 
Ahmad, 2006). One major component of garlic extract, allicin is a sulfur-containing 
compound and has been shown to have significant hypoglycemic activity (Sheela 
and Augusti, 1992). The age-related increase in collagen cross-linking and 
fluorescent products in C57BL/6 mice can be decreased by green tea extract (Rutter 
et al., 2003). The activity of green tea extract is mainly due to tannin components, 
which provide protection against oxidation and glycation (Nakagawa et al., 2002). 
Aloe vera (A. vera) also has antidiabetic and lipid-lowering properties, since oral 
administration of its extract significantly reduced fasting blood glucose level and 
improved lipid profile status in streptozotocin-induced diabetic rats (Rajasekaran et 
al., 2006). The methanol extract of Salacia chinensis stems provides strong 
inhibition against the formation of Amadori compounds and AGEs in addition to its 
anti-hyperglycemic action (Yoshikawa et al., 2003). The seeds of Acacia arabica 
induced hypoglycemic effect in mice by initiating the release of insulin from 
pancreatic beta cells (Yoshikawa et al., 2003). The aqueous extract of Aegle 
marmelos leaves reduces blood sugar and urea and serum cholesterol in diabetic rats 
as compared to the control (Karunanayake et al., 1984).  
Azadirachta indica is widely distributed throughout India. The leaf extracts 
of this plant have anti-hyperglycemic effect in diabetic rats (Chattopadhayay, 1999). 
Ocimum santalum is considered to be a sacred plant in Indian culture. Its aqueous 
extract significantly reduces the blood sugar level in diabetic rats (Vats et al., 2002). 
The aqueous extract of Mangifera indica also proved to have hypoglycemic activity 
which may be due to the reduction of the intestinal absorption of glucose (Aderibigbe 
et al., 1999). Momordica charanta is considered to be very popular antidiabetic and 
antihyperglycemic vegetable in India as well as in other Asian countries. The 
hypoglycemic effect of extracts of its fruit pulp, seed, leaves and whole plant have 
been proved in various animal models (Khanna et al., 1981). Phyllanthus amarus is a 
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herb and is used by the local peoples of south India in treating diabetes. Potent 
antioxidant activity has been found in the methanolic extract of P. amarus. In 
diabetic rats, its extract reduced the blood sugar level (Raphael et al., 2002). In 
addition, several studies have reported the AGE formation and crosslinking 
inhibiting potential of curcumin in diabetic rats (Rahbar and Figarola, 2003).  
Quercetin is a flavonoid and belongs to subclass flavonols (Hartog et al., 1993) 
(Fig. 9) and is widely distributed in many plants: flowers, leaves, and fruits. Quercetin 
possesses strong anti-diabetic activity (Eid et al., 2015). It has the ability to trap MG and 
glyoxal and thus, can inhibit AGEs formation (Li et al., 2014). Quercetin offers 
protection against lipid peroxidation and also provides antioxidant effects in diabetes 
(Groot and Rauen, 1998). It is a strong antioxidant (Afanas’ev et al., 1989). 
1.3. Natural products used in this study   
1.3.1. Thymoquinone (TQ) 
TQ, 2-Isopropyl-5-methyl-1,4-benzoquinone, is one of the most active 
ingredients of Nigella sativa seeds (Rahmani et al., 2014)  (Fig. 10 A and B). Nigella 
sativa is commonly known as black seed or black cumin and is an annual flowering 
plant. It is a member of Ranunculaceae (Nahas and Moher, 2009) and is native to 
southwest Asia. This plant is widely cultivated and distributed in southern Europe, 
northern Africa and Asia Minor (Salem, 2005). It is considered to be a medicine with 
great healing power in the Islamic world. There is a belief that Prophet Muhammad 
(PBUH) said “Use Black seed regularly, since it is a cure for every disease except 
death” (Althaus et al., 1978). The black seeds have been used for the treatment of 
many disease conditions including bronchial asthma, headache, dysentery, infections, 
obesity, back pain, hypertension, gastrointestinal problems (Salem, 2005). They have 
been used for centuries in the traditional system of medicine for example, Ayurveda, 
Unani, Arabic and Chinese medicine. Pharmacologically important activities of the 
black seed include anti-asthma, anti-diarrhoea and anti-dyslipidaemia, antiinflam-
matory, analgesic, antipyretic, antimicrobial and antineoplastic activities (Ali and 
Blunden, 2003). The oil is found to decrease the blood pressure and helps to increase 
the respiration (Ali and Blunden, 2003). Furthermore, the seeds have been reported 
to have potent antioxidant properties both in vitro and in vivo, anti-diabetic, anti-
inflammatory, immunomodulatory, antimicrobial, anti-viral, anti-helminthic,  
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Fig. 9. Chemical structure of quercetin 
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Fig. 10A. Black cumin seeds  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10B. Chemical structure of thymoquinone 
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anti-bacterial, anti-tumour, antihypertensive, galactagogue and insect repelling 
effects (Salem, 2005, Riaz et al., 1996; Siddiqui and Sharma, 1996; Worthen et al., 
1998). Most of the pharmacological properties of black seeds are devoted by quinone 
constituents, and TQ is the prime active component of the volatile black seed oil 
(Aboutabl et al., 1986).  TQ is a potent O2- scavenger and is found to have 
comparable scavenging power as SOD, and it can alter the redox state by scavenging 
ROS including O2-, HO·, H2O2, ONO2· free radicals through modulation of hepatic 
and extrahepatic antioxidant enzymes (Mansour et al., 2002; Hamdy and Taha, 
2009). Furthermore, TQ has been found to offer protection against the kidney 
damage induced by ifosfamide, mercuric chloride, cisplatin and doxorubicin by 
checking renal GSH depletion and antilipid peroxidation product accumulation, 
hence improving renal functioning (Fouda et al., 2008).  
The antioxidant properties of TQ and its metabolite dihydrothymoquinone 
(DHTQ) may play at least in part for the pharmacological action of TQ. For example, 
cellular damage caused by oxidative stress can be clinically prevented by TQ 
(Sankaranarayanan and Pari, 2011). TQ acts as a free radical scavenger, and also 
preserves the activity of various anti-oxidant enzymes such as catalase, glutathione 
peroxidase and glutathione-S-transferase (Sankaranarayanan and Pari, 2011; Syed-
Ahmad et al., 2010; Woo et al., 2012). The anticancer effect(s) of TQ are mediated 
through different modes of action, including antiproliferation, apoptosis, induction, 
cell cycle arrest, ROS generation and antimetastasis/anti-angiogenesis (Woo et al., 
2012). The combination of TQ and conventional chemotherapeutic drugs produce 
greater therapeutic effects and also reduces the toxicity of the latter (Al-Majed et al., 
2006).  
1.3.2. A. vera and aloin 
A. vera is Aloe barbadensis and is a member of the liliaceae (Asphodelaceae) 
family (Surjushe et al., 2008) (Fig. 11A). It is a perennial, shrubby, succulent, 
xerophytic, pea-green coloured plant that grows in arid and subtropical climate. It 
contains several, almost 75 biologically active substances that can be grouped as 
vitamins, minerals, amino acids, enzymes, anthraquinone, saccharides, sugars, lignin, 
salicylic acids and fatty acids (Atherton et al., 1998; Shelton, 1991). A. vera has been 
used as a popular folk medicine throughout history. At least six antiseptic agents 
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including lupeol, salicylic acid, urea nitrogen, cinnamonic acid, phenols and sulphur 
can be obtained from this plant that are capable of killing various pathogens such as 
bacteria, mold and viruses (Rajeshwari et al., 2012). The thick fleshy leaves of Aloe 
plants contain pulp which is used in the food, pharmaceutical, cosmetic and toiletry 
industries (Nejatzadeh-Barandozi, 2013). A. vera has been shown to have several 
benefits including healing properties (Chithra et al., 1998; Heggers et al., 1996), 
protective effect against radiation damage to the skin (Roberts and Travis, 1995; Sato 
et al., 1990) and anti-inflammatory action (Hutter et al., 1996). The benefits of A. 
vera that are not supported by experimental/clinical data are treatment of acne, 
anemia, haemorrhoids, glaucoma, petit ulcer, tuberculosis and blindness (Wani et al., 
2010). Many studies have reported the antioxidant, anti-inflammatory and 
antibacterial activities of A. vera (Lopez et al., 2013; Nejatzadeh-Barandozi, 2013). 
Anti-cancer effects of a compound of A. vera leaves, aloe-emodin has also been 
reported (Lin et al., 2010). A. vera also has antidiabetic and lipid-lowering properties 
since oral administration of the extract significantly reduced fasting blood glucose 
level and improved lipid profile status in streptozotocin-induced diabetic rats 
(Moniruzzaman et al., 2012; Rajasekaran et al., 2006). The phytochemicals present 
in A. vera are tannins, phlobatannins, saponins, flavonoids, steroids, terpenoids and 
cardiac glycosides anthraquinones, which have medicinal value (Sathyaprabha et al., 
2010). Phenolic compounds are the second major substances in A. vera.  
The main active constituent in A. vera extract is aloin, an anthraquinone 
heteroside (Zahn et al., 2008) (Fig. 11B). Its IUPAC name is 8-Dihydroxy-10-(β-D-
glucopyranosyl)-3- hydroxymethyl)-9(10H)-anthracenone (Femenia et al., 1999). The 
antioxidant activity of aloin has been demonstrated (Esmat et al., 2012). Anti-tumour 
activity of aloin has also been reported (Esmat et al., 2005; Fahim et al., 1997). Aloin 
is a potential drug candidate for cancer therapy because it can block the activation of 
STAT3 which causes the inhibition of tumor angiogenesis and growth (Qin-Pan et al., 
2013). It was shown to induce apoptosis in Jurkat cells (Buenz, 2008). Aloin has a 
significant cytotoxic effect in human epithelial type breast and ovarian tumor cell lines 
(Esmat et al. 2006) and in human uterine carcinoma HeLaS3 cells (Niciforovic et al. 
2007) by inducing S-phase cell cycle arrest and apoptosis. It also has chemopreventive 
effects against 1,2-dimethylhydrazine-induced preneoplastic lesions in the colon of 
Wistar rats (Hamiza  et al., 2014).  
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Fig. 11A. Aloe vera plant 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11B. Chemical structure of aloin 
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The antibacterial potential of Aloe depends on the concentration of aloin, 
which because of its glycosides, can easily enter the cells (Tian et al., 2003). Aloin 
has been found to inactivate several enveloped viruses that include Herpes simplex, 
Varicella zoster and Influenza viruses (Sydiskis et al., 1991). Aloin and its 
derivatives have the antitrypanosomal potential (Tewabe et al., 2014). Aloin also 
contributes to the radical scavenging activity of A. vera (Lucini et al., 2014). It has 
also been shown to have excellent laxative effect (Beppu et al., 2003; Park et al., 
2009). Aloin has a protective effect against chronic alcoholic liver injury via 
attenuating lipid accumulation, oxidative stress and inflammation in mice (Cui et al., 
2014).  
1.3.3. Ellagic acid (EA) 
EA is a thermostable polyphenolic molecule (Fig. 12), which is a dimeric 
derivative of gallic acid, and is found in a wide variety of fruits and nuts that include 
raspberries, strawberries, walnuts, grapes, black currants (Zafrilla et al., 2001; Ancos 
et al., 2000), either in its free form, as glycosides, or as in bound form such as 
ellagitannins (Amakura et al., 2000). A high content of EA is found in blackberries, 
strawberries, and raspberries (Rommel and Wrolstad, 1993). Furthermore, 88% of 
the total phenolic content analyzed in raspberry fruits is due to EA (Hakkinen et al., 
1999).  
EA has a strong antioxidant property which is due to its phenolic groups 
(Solon et al., 2000; Festa et al., 2001). It can trap free radicals and hence reduces 
oxidative stress and this property may be very useful in the treatment of several 
diseases. EA has been found to have several beneficial activities including 
antimutagenic, antimicrobial and HIV inhibiting potential (Feldman et al., 1999; 
Akeyama et al., 2001; Vettom and Shetty, 2003; Ruibal et al., 2003), and 
chemoprotective activity (Ahn et al., 1996).  
EA has been shown to maintain the glucose homeostasis in streptozotocin 
induced diabetic rats (Malini et al., 2011). EA and its derivatives can inhibit sorbitol 
accumulation (Ueda et al., 2004). Diseases of the kidney, eye, heart and joints caused 
by high blood glucose levels could be prevented by EA (Ventura-Sobrevella et al., 
2009). It increases the activity of insulin and brings about the reduction of 
inflammation as well as oxidative stress (Seeram et al., 2005). EA was shown to 
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exhibit cytotoxic and antiproliferative activities in lung, colon, breast and prostate 
cancers (Losso et al., 2004). It is postulated that the metastatic factors are inhibited 
by EA which causes the apoptosis of cancer cells (Losso et al., 2004).  Furthermore, 
EA was observed to have more than one mechanism of action to work as antitumor 
agent, either scavenging oxygen species produced by H2O2 treatment or/and 
protecting DNA double helix from injury by alkylating agents (Cozzi et al., 1995). 
Some dietary supplements including EA inhibit mutagenesis and hence have 
anticarcinogenic potential (Hayatsu et al., 1988). EA has been shown to be cytotoxic 
to oral carcinoma cells but not to normal cells (Weisburg et al., 2013). It has been 
reported to induce antiproliferation, cell cycle arrest and death in several human 
cancerous cells (Li et al., 2005; Losso et al., 2004; Mertens-Talcott et al., 2005; 
Narayanan et al., 1999). 
EA is a good antiviral as well as antimicrobial agent (Akiyama et al., 2001). 
It suppresses the growth of pathogens in humans probably by coupling with the 
proteins of the bacterial cell wall, including Bacillus, Staphylococcus and Salmonella 
(Akiyama et al., 2001). Some EA derivatives isolated from the bark of Elaecarpus 
parvifolius have potent antiparasitic activity against Babesia gibsoni (ElKhateeb et 
al., 2005).  
1.3.4. Alliin  
Garlic (Allium sativum L.) is a member of Alliaceae family. It has been used in 
different countries in diet and also as a medicinal agent over centuries. It is widely 
taken in raw form as well as like a medicinal agent against several diseases 
(Jastrzebski et al., 2007; Gorinstein et al., 2006). Garlic has many health beneficial 
properties because of its ability to protect against several diseases. Garlic can be used 
in prevention as well as therapy of several diseases including cardiovascular diseases, 
atherosclerosis, hyperlipidemia, thrombosis, hypertension and diabetes (Agarwal, 
1996). It has been shown to regulate plasma lipid levels (Steiner and Li, 2001) and 
increases the anticoagulant activity of plasma (Apitz-Castro et al., 1992; Ackermann 
et al., 2001). It is used as a remedy in many diseases due to its prophylactic and 
therapeutic action (Bhagyalakshmi et al., 2005; Kabasakal, et al., 2005; Lawson and 
Gardner, 2005). It is found to be effective against a wide number of microorganisms, 
hence it is considered to be a natural antibiotic (Adetumbi and Lau, 1983). The 
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minimum inhibitory concentration of aqueous garlic extract against isolate of 
multidrug resistant bacteria was found to be 5μl/ml (Chowdhury et al., 1991). Garlic 
has been shown to reduce the blood sugar level in streptozotocin treated rat models 
(Patumraj et al., 2000). Furthermore, garlic was also able to reduce the blood glucose 
level in rat models having diabetes mellitus caused by alloxan treatment (Augusti and 
Sheela, 1996; Kumar and Reddy, 1999). These results strongly indicate that garlic has 
antidiabetic properties. The ability of garlic to inhibit cancer has also been reported 
(Dausch and Nixon, 1990; Dorant et al., 1993; Amagase and Milner, 1993; 
Fleischauer and Arab, 2001). Garlic is a rich sources of sulphur containing organic 
compounds such as alk(en)yl cysteine sulphoxides (CSOs), alliin, isoalliin and 
methiin that provide aroma, flavour and health beneficial properties to it.  
Alliin (S-allyl-L-cysteine sulfoxide) is a derivative of an amino acid cysteine, 
and is an organosulfur compound that contains an allyl group, a sulfoxide group and an 
amino acid cysteine (Fig. 13). Alliin has been reported to exhibit several valuable health 
beneficial properties including antidiabetic (Sheela and Augusti, 1992), 
anticholesterolemic (Sheela and Augusti, 1995) and anticarcinogenic (Le Bon et al., 
2003). Alliin was shown to have significant antidiabetic effects in alloxan treated 
diabetic rats (Sheela and Augusti, 1992). It ameliorated the diabetic condition up to 
almost the same point as gibenclamide and insulin did. Furthermore, alliin stimulated 
isolated B cells to secrete insulin in vitro (Augusti and Sheela, 1996). It has the 
potential to scavenge the hydroxyl radicals and this potential is considered to be 
responsible for its biological activities (Lachmann et al., 1994). Cardioprotective effect 
of alliin has also been reported in myocardial infarcted male Wistar rats (Sangeetha and 
Darlin-Quine, 2007; Sangeetha and Darlin-Quine, 2006a; Sangeetha and Darlin-Quine, 
2006b). Garlic and its alliin exhibit anti-inflammatory and antioxidant properties and 
hence have the potential to inhibit the atherosclerosis (Hui et al., 2010). The extract of 
garlic and also alliin has been found to be potent antioxidants (Kourounakis and Rekka, 
1991). Alliin scavenges O2- as well as OH- (Chung, 2006). 
On crushing of garlic, the enzyme alliinase present in garlic converts alliin to 
allicin (diallyl disulfide-oxide) (Amagase et al., 2001; Lawson and Wang, 2001). 
Allicin also exhibits many important properties that include antifungal and 
antibacterial properties (Ilic et al., 2010; Khodavandi et al., 2010; Ankri and 
Mirelman, 1999). 
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Fig. 12. Chemical structure of ellagic acid 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. Chemical structure of alliin 
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1.4. The present study 
Diabetes has become the most common metabolic disease worldwide. 
Hyperglycemia has a key role in the diseases associated with diabetic complications. 
Glycation of proteins plays an important role in the development of physiological and 
pathophysiological processes, such as aging, diabetes, atherosclerosis, 
neurodegenerative diseases, vascular diseases and chronic renal failure (Brownlee, 
1995). SOD, the important antioxidant enzyme in the body which counters the 
deleterious effects of ROS, also gets inactivated by glycation (Jabeen et al., 2006). 
Exposure of SOD to glucose results in its deactivation following by site-speciﬁc and 
random fragmentation (Jabeen et al., 2007). The damage caused by oxidative stress is 
expected to be exacerbated if the antioxidant enzymes themselves are inactivated by 
glycation. Elevated levels of MG have been reported to adversely affect SODs 
particularly against O2-. Exposure of SOD to MG has been shown to cause its 
covalent cross-linking associated with loss of enzymatic activity (Kang, 2003).  
Current antidiabetic therapy is based on synthetic drugs that very often have 
side effects (Codario, 2005). Alternative medicines and natural therapies have 
stimulated new interest of research to find for more efficacious agents with lesser 
side effects. Furthermore, much interest has been developed in the search of natural 
phytochemicals from plants that effectively inhibit glycation and have fewer side 
effects (Coman et al., 2012). Naturally occurring phytochemicals/products have been 
found to be relatively safe for human consumption as compared to synthetic 
compounds, and are relatively non-toxic, inexpensive and are available in an 
ingestible form. A large number of plants and natural biomolecules have been 
discussed in the literature for their antidiabetic effects (Coman et al., 2012; Bailey 
and Day, 1989; Soumyanath, 2006). Some plant extracts and compounds have been 
tested for their antiglycating potential in the past few years (Peng et al., 2011). The 
mechanism is most often not completely understood. 
A large number of hypoglycaemic compounds have antioxidant properties. 
Throughout history black cumin seeds, have been one of the most revered medicinal 
seeds. TQ, an active principle component of the volatile oil of these seeds, possess 
anti-diabetic, anti-oxidant, hepatoprotective, neuroprotective, nephroprotective, anti-
tumor and anti-mutagenic pharmacological activities (El-Mahmoudy et al., 2005; 
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Erkan et al., 2008; Daba and Abdelrahman, 1998; Al-Majed et al., 2006; Fouda et al., 
2008; Gali-Muhtasib et al., 2004; Badary et al., 2003). Garlic and its preparations 
have been traditionally used in food and medicines throughout India. Alliin, the most 
abundant sulfur compound in garlic, has been reported to exhibit several valuable 
health beneficial properties including antidiabetic, anticholesterolemic, 
anticarcinogenic effects (Sheela and Augusti, 1992; Sheela and Augusti, 1995; Le 
Bon et al., 2003). EA is found in a wide variety of fruits and nuts (Zafrilla et al., 
2001; Ancos et al., 2000) and has been found to have several beneficial properties 
including antimutagenic, antimicrobial, antioxidant, HIV inhibiting potential and 
chemoprotective, antidiabetic and antitumor activity (Ahn et al., 1996; Losso et al. in 
2004; Haraguchi et al., 1998; Ueda et a.l, 2004). The main active constituent of A. 
vera extract, aloin has antioxidant, anti-inflammatory, antitrypnosomal, antibacterial 
potential, antiviral and antitumor properties (Esmat et al., 2012; Tian et al., 2003; 
Esmat et al., 2005; Fahim et al., 1997; Tabolacci et al., 2013; Niciforovic et al., 
2007).  
Therefore as discussed above, the natural products TQ, A. vera, and its component 
aloin, EA and alliin have antidiabetic activities. The objective of this study was to 
determine the antiglycating potential of these natural products. The glycation of the 
important antioxidant enzyme, SOD by glucose or MG and its protection by the 
above natural products have been studied by activity, SDS-PAGE, ELISA, 
absorbance, fluorescence and far-UV CD measurements.  
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2. Materials  
The chemicals used for this study were obtained from various sources as 
detailed below. 
Chemical Source 
Alliin, Aloin, Bicinchonic acid (BCA), Bovine 
serum  albumin (BSA), Bromophenol Blue, 
Coomassie blue R-250, Cu,Zn-SOD from Bovine 
erythrocytes, Ellagic acid, Freund’s complete 
adjuvant, Methylglyoxal [40% aqueous solution], 
Nitro blue tetrazolium (NBT), Nicotinamide adenine 
dinucleotide (Reduced) [NADH], O-
Phenylenediamine (OPD), Phenazine methosufate 
(PMS), Thioflavin-T (ThT), N,N, N’,N’ 
Tetramethylene-diamine (TEMED), Thymoquinone 
Sigma Aldrich, U.S.A. 
Acetic acid, Copper sulphate, Dimethyl sulfoxide,                    
Glucose, Glycerol, Methanol, Sodium dodecyl 
sulphate (SDS), Tris hydroxylmethyla-minomethane 
(Tris)  
Qualigens fine chemicals, India 
Acetone, Acrylamide, Ammonium persulphate 
(APS), Hydrochloric acid, β-Mercaptoethanol, N,N’-
Methylene bisacrylamide, Sodium dihydrogen 
phosphate 
Sisco Research Lab, India 
Freund’s incomplete adjuvant, Horseradish peroxide 
(HRP) conjugated goat anti-rabbit IgG, Molecular 
weight protein markers (Broad range) 
Genei Pvt. Ltd. Bangaluru, India 
Disodium hydrogen phosphate, Glycine                                  Himedia 
Sodium bicarbonate, Sodium carbonate, Sodium 
chloride 
Thermo Fischer Scientific, India 
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3. Methods 
3.1. Measurement of SOD concentration and activity 
  Commercial SOD gave a single band in the SDS-PAGE and was hence used 
without purification in the experiments. The concentration of SOD was routinely 
determined by the BCA method using BSA as the standard (Smith et al., 1985). SOD 
stock (1 mg/ml) was made in 20 mM sodium phosphate buffer, pH 7.4 and stored at -
20oC for future use. The activity of SOD was determined spectrophotometrically by 
employing PMS–NADH–NBT system (Nishikimi et al., 1972). The reaction mixture 
consisted of 20 mM sodium phosphate buffer (pH 8.2), PMS (1.9 µM), NBT (184 
µM) and NADH (205 µM). All solutions were prepared at ambient temperature in 
glass vessels under subdued fluorescent room light. For assaying, SOD enzyme was 
pipette into a cuvette at room temperature (25oC) containing freshly prepared NBT 
and NADH. The reaction was initiated with the addition of freshly prepared PMS and 
the absorbance at 560 nm was continuously monitored as an index of NBT reduction 
using a single beam Shimadzu spectrophotometer. Reagent control lacking the 
enzyme was taken. 
3.2. Electrophoresis   
  Sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed according to the method of Laemmli (1970) using 15 % separating and 
5 % stacking gels. Protein bands were visualized by overnight staining with 0.1 % 
(w/v) Coomassie Brilliant Blue R 250. The gels were destained using 40 % (v/v) 
methanol/ 10 % (v/v) acetic acid. Commercial SOD gave a single band in the SDS-
PAGE and was hence used without further purification in the experiments. 
3.3. Immunization of rabbits and purification of IgG 
  Antibodies were raised in the rabbits by injecting SOD emulsified in Freund’s 
complete/incomplete adjuvant. Healthy male albino rabbits, weighing 2.5-3 kg 
received subcutaneously 300 μg of antigen dissolved in 0.5 ml of 20 mM  sodium 
phosphate buffer pH  7.2, mixed and emulsified with equal volume of Freund’s 
complete adjuvant (FCA) as first dose. The animals were rested for 21 days and then 
boosted weekly with 150 μg of antigen in 0.5 ml of sodium phosphate buffer 
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emulsified with equal volumes of Freund’s incomplete adjuvant (FIA), for three 
consecutive weeks. Five days after final booster, the animals were bled through a 
marginal ear vein and blood (30 ml) was allowed to clot at room temperature for 6-8 
h. Serum was then collected by centrifugation at 1600 x g for 15 min, 
decomplemented at 56oC for 30 min and preserved at -20oC. Formation of SOD 
specific antibodies was monitored by ELISA. IgG from the serum of immunized 
rabbits was purified to homogeneity on DEAE-cellulose matrix after ammonium 
sulphate precipitation according to the procedure followed in our laboratory (Rehan 
and Younus, 2006). 
3.4. Enzyme-linked immunosorbent assay (ELISA) 
  The cross-reactivity of the antibodies with SOD was determined by ELISA. 
Ninety six-well microtitre plates (Roll Piove di Sacco, Italy) were coated overnight 
with 100 µl of SOD (5 µg/ml) in 0.05 M carbonate-bicarbonate buffer, pH 9.6 at 4oC. 
After extensive washing with phosphate buffered saline (PBS)-Tween 20 buffer, 150 
µl of blocking buffer (5% BSA in PBS) was applied to the wells and the plates 
incubated at 37oC for 2 h. After removal of the blocking buffer 100 µl of anti-SOD 
IgG (16 µg/ml) was added and the binding was allowed to proceed at 37oC for 2 h. 
The microtitre plates were washed and incubated with 100 µl of HRP conjugated goat 
anti-rabbit IgG at 37oC for 1 h. After the usual washing steps, the peroxidise reaction 
was initiated by the addition of the substrate OPD/H2O2, arrested by the addition of 1 
M H2SO4, and absorbance at 490 nm measured in an ELISA reader. 
3.5. In vitro glycation of SOD by glucose, MG  or a combination of both 
SOD was dissolved in 20 mM sodium phosphate buffer, pH 7.4 to make a 
stock of    1 mg/ml. Stock was then stored at -20oC for future use. In order to induce 
glycation, SOD (0.2 mg/ml) was incubated along with 0.5 M glucose, 10 mM MG or 
a combination of 0.5 M glucose and 10 mM MG in 20 mM sodium phosphate buffer 
pH 7.4 containing 0.15 M NaCl. Incubations were performed in autoclaved tubes in 
order to maintain sterile conditions during the prolonged incubations. No bacterial 
growth was detected during the periods of incubation. The incubations were carried 
out in a shaking water bath at 37oC for 1 h, 1 day, 5 days and 10 days. The existence 
of free glucose or MG in the SOD protein solutions after incubation was found to 
have no effect on the enzyme activity at room temperature. Therefore, these solutions 
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were not dialyzed after incubation. The native SOD incubated with phosphate buffer 
(20 mM, pH 7.4 containing 0.15 M NaCl) alone served as the control. Glucose or MG 
or combination of both glucose and MG-induced glycation of SOD was assessed by 
activity, SDS-PAGE, ELISA, absorption, intrinsic fluorescence, AGEs specific 
fluorescence, thioflavin (ThT) fluorescence and Far-UV circular dichroism (CD) 
spectroscopic studies. 
3.6. Preparation of stock solutions of natural products 
A. vera plants were harvested in the month of November from the plant 
nursery, Aligarh Muslim University, Aligarh, India. The fresh leaves were dissected 
into two halves and the inner colourless, mucilaginous pulp was homogenized in an 
electrical blender, centrifuged at 10,000 g at 4oC for 15 min to remove the fibres. The 
resultant supernatant was filtered, freeze dried at -20oC and lyophilized. To make a 
stock solution of A. vera extract, 30 mg of the lyophilized powder was dissolved in 
100% DMSO. 5 mM stocks of TQ, aloin and EA, each were freshly prepared in 100% 
DMSO. 5 mM stock alliin was prepared in 20 mM phosphate buffer, pH 7.4.  
3.7. Effect of natural products on the glycation of SOD 
SOD (0.2 mg/ml) in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 
M NaCl was incubated with 0.5 M glucose or 10 mM MG or combination of 0.5 M 
glucose and 10 mM MG for 10 days at 37oC in the presence of 0, 10, 20 and 50 µg/ml 
of A. vera extract or 0, 10, 20 and 50 µM TQ, aloin, EA or alliin. Since, TQ, aloin and 
EA were dissolved in DMSO, the final DMSO concentration in the incubation 
mixture was 1%. The effect of A. vera extract, TQ, aloin, EA and alliin on the 
glycation of SOD with glucose or MG or a combination of both were assessed by 
activity, SDS-PAGE, ELISA, absorption, intrinsic fluorescence, AGEs specific 
fluorescence and ThT fluorescence spectroscopic studies. Far-UV CD studies were 
performed for Alliin but not for other natural products as DMSO in these samples 
interfered with the measurements in this wavelength range. 
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3.8. Biophysical studies on the glycation of SOD and its protection by                    
natural products 
3.8.1. Absorption Spectroscopy 
Absorbance measurements were carried out on a double beam Perkin Elmer 
spectrophotometer (Lambda 25). The absorbance measurements in the case of 
glycation of SOD and its protection by TQ were performed using an old UV lamp that 
got changed in the latter experiments, therefore, the values of absorbance were much 
lower in the experiments on the glycation of SOD and its protection by TQ as 
compared to the latter experiments. The spectra of SOD (0.2 mg/ml) in 
absence/presence of glucose or MG and absence/presence of TQ, A. vera, aloin, EA 
or alliin were measured in the wavelength range of 240-500 nm. 
3.8.2. Fluorescence Spectroscopy 
  All fluorescence measurements were carried out on a Shimadzu 
spectrofluorometer (model RF-5301PC). The fluorescence measurements in the case of 
glycation of SOD and its protection by TQ were performed using an old fluorescent 
lamp that got changed in the latter experiments, therefore, the values of fluorescence 
intensity were much lower in the experiments on the glycation of SOD and its 
protection by TQ as compared to the latter experiments. The intrinsic fluorescence of 
SOD (0.2 mg/ml) incubated alone, with glucose or with MG in the absence/presence of 
TQ, A. vera extract, aloin, EA or alliin was monitored with excitation at 280 nm and 
emission in the range 290-400 nm. The slit widths were 5 nm for both excitation and 
emission. The formation of fluorescent AGE products was monitored with excitation at 
350 nm and emission in the range 400-480 nm. The slit widths were 3 nm for both 
excitation and emission. The fibrillar state of incubated SOD was determined via ThT, a 
reagent used for detecting the β-sheet configuration in proteins (Schmitt et al., 2005). 
The fluorescence of the above incubation mixtures was monitored after adding 6 µM 
ThT reagent at excitation wavelength of 440 nm and the emission was measured in the 
range 450-600 nm. The slit widths were 10 nm for both excitation and emission.  
3.8.3. CD-Spectroscopy 
Far-UV CD measurements were carried out with a Jasco spectropolarimeter 
(J-815) equipped with a Jasco Peltier-type temperature controller (PTC-424S/15). The 
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instrument was calibrated with D-10-camphorsulphonic acid. The spectra were 
collected in a cell of 0.1 cm with scan speed of 100 nm/min and response time of 1 S. 
Each spectrum was the average of 2 scans.  
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4. Results and Discussion 
4.1. SOD purity and activity 
SOD is a dimeric protein of molecular mass of 32 kDa (Bannister et al., 1971). 
The enzyme migrated as a single band (16 kDa) (Fig. 14) in SDS-PAGE and hence, it 
was homogenous and, therefore, it was used in the experiments without further 
purification.  
The activity of SOD was determined by PMS-NADH-NBT assay under 
standard assay conditions. The observed spontaneous NBT reduction by O2- was 
inhibited in a concentration-dependent manner up to 3 μg by SOD (Fig. 15). The 
enzyme activity increased linearly up to 0.5 μg of the enzyme, after which the 
increase in activity was slow. 
4.2. In vitro glycation of SOD by glucose, MG or both 
It has been reported that prolonged incubation of enzymes with reducing 
sugars results in glycation and hence inactivation (Monnier and Cerami, 1981; 
Brownlee et al., 1984; Wells-Knetch et al., 1995). MG is a highly reactive α-
oxoaldehyde that plays an important role in glycation reactions, formation of AGEs 
and other complications associated with hyperglycemia and related disorders (Jabeen 
et al., 2006). SOD is possibly the most important antioxidant enzyme that is 
specifically involved in the detoxification of O2-, enabling cells to cope with lethal 
oxidative environments. SOD itself has been shown to undergo glycation by reducing 
sugars and MG and hence inactivation (Jabeen et al., 2006; Jabeen and Saleemuddin, 
2006). SOD was incubated with high non-physiological concentration of glucose (0.5 
M) or MG (10 mM) enzyme which may serve as an appropriate model for the long-
term effects of glucose or MG on the enzyme (Jabeen et al., 2006; Coussons et al., 
1997). Glycation-induced changes in the enzyme were evaluated by activity, SDS-
PAGE, ELISA, UV absorption, fluorescence and CD studies. 
4.2.1. Activity studies 
The effect of 0.5 M glucose or 10 mM MG or a combination of 0.5 M glucose 
and 10 mM MG on the activity of SOD is shown in Fig. 16. Incubation with               
glucose at 37oC resulted in a decrease in the activity of SOD. At the end of ten days of  
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Fig. 14. SDS-PAGE of SOD. Commercial SOD was analyzed by 15% SDS-PAGE. 
Molecular weight markers (Genei) were applied to lane 1. Lane 2 contained 10 µg of 
SOD. The gels were stained with coomassie brilliant blue. 
 
 
 
 
 
 
 
Fig. 15. Inhibition of NBT reduction by SOD under aerobic conditions. Different 
amounts of purified SOD were added to the reaction mixture containing NBT and 
NADH under standard assay conditions. The reaction was initiated with the addition 
freshly prepared PMS and was monitored for 120 seconds at 560 nm. 
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Fig. 16. Effect of glycation on the activity of SOD. SOD (0.2 mg/ml) was incubated 
alone (Panel 1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination 
of 0.5 M glucose and 10 mM MG (Panel 4) for 1 (♯), 5 (≡) and 10 (░)  days at 37oC. 
Each Panel also shows native SOD (0.2 mg/ml) alone in buffer that was not incubated 
at 37oC for any time period (■). The enzyme activity was then determined under 
standard assay conditions.  
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incubation with glucose, the resultant activity was 72% of the control. MG, which is 
more reactive than glucose in the Maillard reaction inactivated SOD more rapidly. At 
the end of ten days of incubation with MG or a combination of glucose and MG, the 
residual activity was 46% and 37% of the control, respectively. SOD did not lose 
significant activity when incubated alone i.e., in the absence of glucose or MG. The 
residual activity in this case was 93% after 10 days of incubation. 
4.2.2. SDS-PAGE  
SDS-PAGE of SOD incubated at 37oC for various days in the absence of 
glucose or MG exhibited very slight decrease in the intensity of enzyme band (Fig. 
17A). This is correlated with the activity results that have shown the retention of 93% 
activity after 10 days of incubation for SOD incubated alone. However, SOD 
incubated with glucose revealed a significant decrease in in the staining intensity of 
the band corresponding to the enzyme (Fig. 17B). The band appeared more lighter 
with an increase in the duration of exposure to the sugar, presumably indicating its 
crosslinking and/or degradation into small peptides. Formation of high molecular 
weight cross-linked aggregates in the SOD exposed to MG or a combination of MG 
and glucose is evident from figure 17C and 17D, respectively. The high molecular 
weight bands started appearing within 1 h of incubation and their intensity increased 
with days of incubation. After ten days of incubation, no band corresponding to the 
free enzyme (uncross linked) was visible in the gel. The effect of MG is thought to be 
due to its ability to form stable heterocyclic compounds that cross-link protein. These 
changes in the enzyme preparation exposed to both glucose and MG were slightly 
faster as compared to that exposed only to MG. However, the effect of MG dominates 
over the effect of glucose, since MG is much more reactive and potent glycating agent 
as compared to glucose. 
4.2.3. ELISA 
Incubation of SOD alone or with glucose, MG and both glucose and MG 
results in a decrease in absorbance at 490 nm in ELISA indicating reduced cross-
reactivity with anti-SOD antibodies, which we believe is due to the structural/ 
chemical modification of the epitopes of enzyme due to incubation at 37oC and by 
glycation (Fig. 18). When SOD is incubated for increasing days  at 37oC with glucose 
(Fig. 18, Panel 2), MG (Fig. 18, Panel 3)  or both glucose and MG (Fig. 18, Panel 4),  
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Fig. 17. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG for various time 
periods at 37oC. Lane 1 shows molecular weight markers (Genei); Lanes 2, 3, 4, 5 
and 6 show SOD (10 μg) incubated alone, with glucose, with MG or with a 
combination of glucose and MG for 0 h, 1h, 1 day, 5 days and 10 days, respectively. 
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Fig. 18. Effect of glycation of SOD on the cross-reactivity (ELISA) of anti-SOD 
antibodies with the enzyme. SOD (0.2 mg/ml) was incubated alone (Panel 1), with 
0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination of 0.5 M glucose 
and 10 mM MG (Panel 4 ) for 1 day (♯), 5 days (≡) and 10 days (░) in 20 mM sodium 
phosphate buffer, pH 7.4 at 37oC. Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■). Each value 
represents the average for two independent experiments performed in triplicates. 
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for 1 day, 5 days and 10 days, a progressive decrease in absorbance at 490 nm (cross-
reactivity with anti-SOD antibodies). Therefore, this experiment shows that glycation 
induces structural/chemical changes in enzyme incubated with glucose, MG or a 
combination of both, at 37oC. Native SOD incubated till 10 days at 37oC (control), no 
or very slight decrease in absorbance was observed (Fig. 18, Panel 1). 
4.2.4. UV absorption studies 
Bovine erythrocyte Cu,Zn-SOD lacks tryptophan residues and has one 
tyrosine residue per subunit. SOD that had not been incubated with glucose or MG 
(native SOD) gave absorbance in the wavelength range 250-300 nm, whereas in 
glucose, MG or a combination of glucose and MG glycated (Fig. 19) samples with 
increasing days of incubation, an increasing hyperchromicity was observed. Native 
SOD incubated till 10 days at 37oC (control), no or very slight increase in absorbance 
at 280 nm was observed (Fig. 19, Panel 1). The increase in absorbance was much 
more and faster in the case of SOD incubated with MG than with glucose, implying 
that the structural changes in the enzyme were much more and faster with MG than 
with glucose (Fig. 19, Panel 3 and 2, respectively). And the increase in absorbance 
was the most and fastest in the case of SOD incubated with a combination of both 
glucose and MG (Fig. 19, Panel 4) and is similar to the effect of MG alone since MG 
is a stronger glycating agent than glucose hence the effect of MG dominates over the 
effect of glucose. The observed hyperchromicity in the case of glucose incubated 
SOD could be due to modification of aromatic amino acids or changes in the micro 
environment of aromatic amino acids of the enzyme. The observed hyperchromicity 
in the case of MG or glucose + MG could be due to change in the conformation of 
SOD due to glycation induced unfolding leading to cross-liking and aggregation.  
4.2.5. Intrinsic fluorescence studies 
Total intrinsic fluorescence of native and glycated SOD was measured by 
exciting at 280 nm. Native SOD gave an emission peak at 310 nm, whereas in 
glucose, MG or a combination of glucose and MG glycated samples with increasing 
days of incubation, an increasing fluorescence quenching was observed (Fig. 20). In 
the control sample, no or very slight fluorescence quenching at 310 nm was observed 
(Fig. 20, Panel 1). Therefore, glycation induced structural changes in SOD incubated 
with glucose or MG or a combination of both (fFg. 20, Panel 2, 3 and 4, respectively).  
57 
 
 Fig. 19. Effect of glycation of SOD on the absorbance of the enzyme. Absorbance 
at 280 nm for samples of SOD (0.2 mg/ml)  incubated for 1 day (♯), 5 days (≡) and 10 
days (░) in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone 
(Panel 1) and with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or with a 
combination of 0.5 M glucose and 10 mM MG (Panel 4). Each Panel also shows 
native SOD (0.2 mg/ml) alone in buffer that was not incubated at 37oC for any time 
period (■). Each value represents the average for two independent experiments 
performed in triplicates. 
 
 
 
 
 
Fig. 20. Effect of glycation of SOD on the intrinsic fluorescence of the enzyme. 
Fluorescence intensity at the excitation/emission wavelengths of 280/310 nm for 
samples of SOD (0.2 mg/ml) incubated for 1 day (♯), 5 days (≡) and 10 days (░) in 20 
mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and 
with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or with a combination of 0.5 M 
glucose and 10 mM MG (Panel 4). Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■). Each value 
represents the average for two independent experiments performed in triplicates. 
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Fluorescence quenching was much more and faster for MG than for glucose 
incubated enzyme, implying again that MG incubation has a greater effect on the 
structure of SOD than glucose incubation. And incubation of SOD with both glucose 
and MG resulted in even more and faster fluorescence quenching than MG alone 
incubated enzyme implying greatest structural change in this case. 
4.2.6. AGEs specific fluorescence studies 
We have followed the formation of AGEs in the samples via autofluorescence 
(Schmitt et al., 2005). Fluorescent AGEs specific fluorescence of native and glycated 
SOD was measured by exciting at 350 nm. The control sample showed no 
fluorescence in the wavelength range 400-480 nm. Whereas SOD incubated with 
glucose, MG or a combination of glucose and MG showed AGEs specific 
fluorescence in the wavelength range 400-480 nm which increased with increasing 
days of incubation (Fluorescence enhancement) (Fig. 21, Panel 2, 3, 4, respectively). 
The fluorescence enhancement observed in the case of glucose incubated SOD was 
low, implying few AGEs formed in this case (Fig. 21, Panel 2). However, the 
enhancement was much more and faster in the case of MG incubated enzyme, 
implying formation of larger quantity of AGEs (Fig. 21, Panel 3). And incubation of 
SOD with both glucose and MG resulted in even more and faster fluorescence 
enhancement than MG alone incubated enzyme implying greatest quantity of AGEs 
formed in this case (Fig. 21, Panel 4). The spectra of fluorescence intensity versus 
wavelength (400-480 nm) were rather broad (data not shown), and this probably 
reflects the presence of a number of different fluorescent compounds being formed 
during glycation. 
4.2.7. ThT fluorescence studies 
ThT is a dye that interacts with the fibrillar structure of proteins, upon 
interaction its fluorescence intensifies, while in its free form is only weakly 
fluorescent. This quality has been employed in the detection of amyloid fibril 
structures in proteins (Schmitt et al., 2005). The control sample showed very slight 
enhancement in the fibrillar state (Fig. 22, Panel 1). Whereas SOD incubated with 
glucose, MG or a combination of glucose and MG showed enhancement in the 
fibrillar state, which increased with increasing days of incubation (Fluorescence 
enhancement) (Fig. 22, Panel 2, 3, 4, respectively). The fibrillar state enhancement  
59 
 
 Fig. 21. Effect of glycation of SOD on the AGEs specific fluorescence of the 
enzyme. AGEs specific fluorescence intensity at the excitation/emission wavelengths 
of 350/450 nm for samples of SOD (0.2 mg/ml) incubated for 1 day (♯), 5 days (≡) and 
10 days (░) in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone 
(Panel 1) and with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or with a 
combination of 0.5 M glucose and 10 mM MG (Panel 4). Each Panel also shows 
native SOD (0.2 mg/ml) alone in buffer that was not incubated at 37oC for any time 
period (■).  
 
 
 
Fig. 22. Effect of glycation of SOD on the ThT fluorescence of the enzyme. ThT 
fluorescence intensity at the excitation/emission wavelengths of 440/480 nm for 
samples of SOD (0.2 mg/ml) incubated for 1 day (♯), 5 days (≡) and 10 days (░) in 20 
mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and 
with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or with a combination of 0.5 M 
glucose and 10 mM MG (Panel 4). Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■). 
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observed in the case of both glucose and MG incubated SOD was the most, followed 
by MG incubated enzyme, and then by glucose incubated enzyme. Therefore, fibrils 
were formed in all the three cases. 
4.2.8. CD studies 
Far-UV CD studies in the 200-250 nm wavelength range were performed to 
measure the changes in the secondary structure of SOD upon glycation. Native SOD 
gave a negative peak at 208 nm, whereas in glucose, MG or a combination of glucose 
and MG glycated samples with increasing days of incubation, a progressive decrease 
in the negative ellipticity was observed (Fig. 23, Panel 2, 3, 4, respectively). In the 
control sample, very slight decrease in negative ellipticity occurred (Fig. 23, Panel 1). 
Therefore, glycation induced changes in the secondary structure of SOD in all the 
above three cases. However, the decrease in negative ellipticity was more and faster 
for MG than for glucose incubated enzyme, implying that MG incubation has a 
greater effect on the secondary structure of SOD than glucose incubation. And 
incubation of SOD with both glucose and MG resulted in even more and faster 
secondary structural changes than MG alone.  
4.3. Protective effect of TQ on the glycation of SOD with glucose or MG 
4.3.1. Activity studies 
 The effect of TQ on the glycation of SOD by 0.5 M glucose or 10 mM MG 
was studied. Fig. 24 shows the increase in activity of SOD incubated for ten days at 
37oC alone in the absence of glucose or MG and that incubated in the presence of 
glucose, MG or a combination of both and with increasing concentration of TQ. SOD 
incubated alone with TQ showed a slight increase in its activity i.e. the activity 
increased by 2% when the enzyme was incubated with 50 µM TQ as compared to the 
control (the sample that had no TQ) (Fig. 24, Panel 1). This 2% increase in activity of 
SOD is believed to be due the antioxidant property of TQ. SOD incubated with 
glucose, MG or a combination of both and TQ showed a greater increase in activity as 
compared to the enzyme that was not incubated with glucose or MG. The activity 
increased by 9.6%, 7.7% and 6.2% as compared to the control when the enzyme was 
incubated with glucose, MG or a combination of both glucose and MG, respectively, 
and TQ (Fig. 24, Panel 2, 3, 4, respectively). This observed further increase in activity  
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Fig. 23. Effect of glycation of SOD on far-UV CD of the enzyme. CD at 208 nm for 
samples of SOD (0.2 mg/ml) incubated for 1 day (♯), 5 days (≡) and 10 days (░) in 20 
mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and 
with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or with a combination of 0.5 M 
glucose and 10 mM MG (Panel 4). Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■).  
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Fig. 24. Effect of TQ on the activity of SOD incubated with glucose, MG or 
combination of both glucose and MG. SOD (0.2 mg/ml) was incubated alone (Panel 
1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination of 0.5 M 
glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (#), 10 (≡), 
20 (□) and 50 µM (░) concentration of TQ. Each Panel also shows native SOD (0.2 
mg/ml) alone in buffer that was not incubated at 37oC for any time period (■). The 
enzyme activity was then determined under standard assay conditions. Each value 
represents the average for three independent experiments performed in duplicates. 
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is believed to be due to the antiglycating activity of TQ. The increase in activity was 
more in the case of glucose than for MG or MG and glucose. Therefore, it appears 
that TQ is a more effective antiglycating agent for sugars/compounds that are milder 
glycating agents. 
4.3.2. SDS-PAGE  
The protective effect of TQ on SOD fragmentation/cross-linking induced by 
glycation is seen in Fig. 25. SDS-PAGE of SOD incubated for ten days in the absence 
of glucose or MG showed a slight increase in staining intensity with increasing TQ 
concentration (Fig. 25A). This correlates with 2% increase in activity with 50 µM TQ. 
However, the enzyme incubated for ten days with glucose showed a more increase in 
staining intensity with increasing TQ concentration (Fig. 25B). SOD incubated for ten 
days with MG (Fig. 25C) or a combination of both glucose and MG (Fig. 25D) 
exhibited a very slight decrease in the bands corresponding to the cross-linked 
aggregates with increasing TQ concentration. Therefore, it is evident from SDS-
PAGE analysis that TQ slightly protected SOD against fragmentation/cross-linking 
induced by glycation. The protection appears to be in the following order for the 
enzyme incubated with glucose ˃ MG ˃ glucose + MG ˃ no glycating compound. 
This correlates with the activity observations. 
4.3.3. UV absorption studies 
As observed earlier, glycation of SOD by glucose, MG and both glucose and 
MG results in hyperchromicity (structural changes) (Fig. 19). When SOD is incubated 
for 10 days at 37oC with glucose, MG or both glucose and MG and increasing 
concentration of TQ, a progressive decrease in absorbance at 280 nm with increasing 
TQ concentration was observed in all the three cases (Fig. 26, Panel 2, 3 and 4, 
respectively). SOD incubated alone for 10 days with increasing TQ concentration 
(control) exhibited no decrease in absorbance at 280 nm (Fig. 26, Panel 1). Therefore, 
TQ protected the enzyme to some extent against the structural changes induced by 
glycation with glucose, MG or a combination of both, and the protection increased 
with increasing concentration of TQ. However, the enzyme was still far from the 
structure of the native enzyme even at 50 µM concentration of TQ in all the three 
cases. It was observed that the absorbance at 280 nm for samples of SOD incubated 
for 10 days with glucose, MG or both and without TQ but 1% DMSO was higher than  
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Fig. 25. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG (D) and with 
varying concentration of TQ for 10 days at 37oC. Lane 1 shows molecular weight 
markers (Genei); Lane 2 shows SOD (10 μg) that has not been incubated with 
glucose, MG or TQ. Lanes 3, 4, 5 and 6 show SOD (10 μg) incubated for 10 days 
alone or with glucose, MG or a combination of glucose and MG and with 0, 10, 20 
and 50 μM TQ, respectively. 
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the same samples incubated without TQ and DMSO. Therefore, it appears that even 
1% DMSO present in the incubation mixtures decreases the stability of SOD at 37oC 
and hence makes it more prone to glycation. It has also been observed in the case of 
myoglobin and concanavalin A that low concentration of DMSO reduces the thermal 
stability of both proteins (Jackson and Mantsch, 1991). 
4.3.4. Intrinsic fluorescence studies 
As observed earlier, glycation of SOD by glucose, MG and both glucose and 
MG results in intrinsic fluorescence quenching (structural changes) (Fig. 20). When 
SOD is incubated for 10 days at 37oC with glucose, MG or both glucose and MG and 
increasing concentration of TQ, a progressive increase in fluorescence at 310 nm with 
increasing TQ concentration was observed in all the three cases (Fig. 27, Panel 2, 3, 
4). The control exhibited insignificant increase in fluorescence at 310 nm (Fig. 27, 
Panel 1). Therefore, again this experiment shows that TQ protected the enzyme to 
some extent against the structural changes induced by glycation with glucose, MG or 
a combination of both, and the protection increased with increasing concentration of 
TQ. However, it was observed that SOD incubated for 10 days at 37oC with glucose, 
without TQ but with 1% DMSO showed fluorescence enhancement and not 
quenching. Therefore, it appears that DMSO somehow perturbs the environment 
around the aromatic residues of the protein which affects their fluorescence.  
4.3.5. AGEs specific fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of TQ (Fig. 28, Panel 2, 3 and 4, respectively), 
a progressive decrease in AGEs specific fluorescence at 450 nm with increasing TQ 
concentration was observed in all the three cases. The control exhibited insignificant 
decrease in fluorescence at 450 nm (Fig. 28, Panel 1). Therefore, TQ protected the 
enzyme to some extent against formation of AGEs induced by glycation with glucose, 
MG or a combination of both, and the protection increased with increasing 
concentration of TQ.  
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Fig. 26. Effect of  TQ on the absorption changes induced in SOD due to 
glycation. Absorbance at 280 nm for samples of SOD (0.2 mg/ml) that were 
incubated in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone 
(Panel 1) and with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a combination 
of 0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 
(♯), 10 (≡), 20 (□) and 50 (░) µM TQ. Each Panel also shows native SOD alone in 
buffer that was not incubated at 37oC for any time period (■). 
  
 
 
 
 
Fig. 27. Effect of TQ on the intrinsic fluorescence changes induced in SOD due to 
glycation. Fluorescence intensity at the excitation/emission wavelengths of 280/310 
nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium phosphate 
buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M glucose (Panel 
2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 mM MG (Panel 
4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM TQ. 
Each Panel also shows native SOD alone in buffer that was not incubated at 37oC for 
any time period (■). 
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4.3.6. ThT fluorescence studies 
As observed earlier, glycation of SOD by glucose, MG and both glucose and 
MG results in ThT fluorescence enhancement (formation of fibrils) (Fig. 21). When 
SOD is incubated for 10 days at 37oC with glucose, MG or both glucose and MG and 
increasing concentration of TQ, a progressive decrease in ThT fluorescence at 480 nm 
with increasing TQ concentration was observed in all the three cases (Fig. 29, Panel 2, 
3 and 4, respectively). The control exhibited insignificant decrease in ThT 
fluorescence at 480 nm (Fig. 29, Panel 1). Therefore, TQ protected the enzyme to 
some extent against formation of fibrils induced by glycation with glucose, MG or a 
combination of both, and the protection increased with increasing concentration of 
TQ. It was again observed that the presence of 1% DMSO in the incubation mixtures 
decreases the stability of SOD at 37oC and hence makes it more prone to glycation 
and subsequent fibril formation.  
4.4. Protective effect of A. vera and aloin on the glycation of SOD with glucose or MG 
4.4.1. Activity studies 
The effect of A. vera extract and aloin on the activity of SOD glycated by 0.5 
M glucose or 10 mM MG was studied. Fig. 30 shows the remaining activity of SOD 
incubated for ten days at 37oC alone, and that incubated in the presence of glucose, 
MG or a combination of both and with increasing concentration of A. vera extract (A) 
or aloin (B). SOD incubated for ten days alone with A. vera extract or aloin showed a 
slight increase in activity with increasing A. vera extract or aloin concentration (Fig. 
30A and 30B, Panel 1). The activity increased by 4.4 and 5.4% when the enzyme was 
incubated with 50 µg/ml of A. vera extract or 50 µM aloin, respectively as compared 
to the control (the sample that had no A. vera extract or aloin). This increase in 
activity of SOD is believed to be due to the antioxidant property of A. vera extract and 
aloin. SOD incubated with glucose, MG or a combination of both, and A. vera extract 
or aloin showed a greater increase in activity as compared to the enzyme that was not 
incubated with glucose or MG. The activity increased by 10.0, 7.4 and 7.0% as 
compared to the control when the enzyme was incubated with glucose (Fig. 30A, 
Panel 2), MG (Fig. 30A Panel 3) or a combination of both glucose and MG (Fig. 30A, 
Panel 4), respectively, and 50 µg A. vera extract. The activity increased by 14.6, 10.1 
and 9.8% as compared to the control when the enzyme was incubated with glucose  
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Fig. 28. Effect of TQ on the fluorescent AGEs formed of SOD due to glycation. 
AGEs specific fluorescence intensity at the excitation/emission wavelengths of 
350/450 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µM TQ. Each Panel also shows native SOD alone in buffer that was not incubated 
at 37oC for any time period (■). 
 
 
 
 
 
 
 
Fig. 29. Effect of TQ on the fibrils formed in SOD due to glycation. ThT 
fluorescence intensity at the excitation/emission wavelengths of 440/480 nm for 
samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium phosphate buffer, 
pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M glucose (Panel 2) or 
10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 mM MG (Panel 4) 
for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM TQ. Each 
Panel also shows native SOD alone in buffer that was not incubated at 37oC for any 
time period (■). 
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Fig. 30. Effect of A. vera extract or aloin on the activity of SOD incubated with 
glucose, MG or both. SOD (0.2 mg/ml) was incubated alone (Panel 1), with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µg/ml of A. vera extract (A) or µM aloin (B). Each Panel also shows native SOD 
(0.2 mg/ml) alone in buffer that was not incubated at 37oC for any time period (■). 
The enzyme activity was then determined under standard assay conditions. Each value 
represents the average for three independent experiments performed in duplicates. 
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(Fig. 30B, Panel 2), MG (Fig. 30B Panel 3) or a combination of both glucose and MG 
(fig. 30B Panel 4), respectively, and 50 µM aloin. This observed further increase in 
activity is believed to be due to the antiglycating activity of A. vera extract and aloin. 
The increase in activity was more in the case of glucose than for MG or both MG and 
glucose. Therefore, it appears that A. vera extract and aloin is a more effective 
antiglycating agent for sugars/compounds that are milder glycating agents. 
4.4.2. SDS-PAGE  
The protective effect of A. vera extract and aloin on SOD fragmentation/cross-
linking induced by glycation is seen in Fig. 31 and 32, respectively. SDS-PAGE of 
SOD incubated for ten days in the absence of glucose or MG showed same staining 
intensity with increasing A. vera extract or aloin concentration (Fig. 31A and 32A, 
respectively). However, the enzyme incubated for ten days with glucose showed a 
more increase in staining intensity with increasing A. vera extract or aloin 
concentration (Fig. 31B and 32B, respectively). SOD incubated for ten days with MG 
(Fig. 31C and 32C) or a combination of both glucose and MG (Fig. 31D and 32D) 
exhibited a decrease in the bands corresponding to the cross-linked aggregates with 
increasing A. vera extract (Fig. 31C and 31D) or aloin (Fig. 32C and 32D) 
concentration. In fact in the case of MG alone, there was a slight increase in the band 
corresponding to the native enzyme with increasing A. vera extract or aloin 
concentration. Therefore, it is evident from SDS-PAGE analysis that A. vera extract 
and aloin protected SOD against fragmentation/cross-linking induced by glycation.  
4.4.3. ELISA 
Incubation of SOD alone or with glucose, MG and both glucose and MG 
results in a decrease in absorbance at 490 nm in ELISA indicating reduced cross-
reactivity with anti-SOD antibodies, which we believe is due to the 
structural/chemical modification of the epitopes of enzyme due to incubation at 37oC 
and by glycation. When SOD is incubated for 10 days at 37oC alone or with glucose, 
MG or both glucose and MG and increasing concentration of A. vera extract (Fig. 
33A Panel 1, 2, 3 and 4, respectively) or aloin (Fig. 33B Panel 1, 2, 3 and 4, 
respectively), a progressive increase in absorbance at 490 nm (cross-reactivity with 
anti-SOD antibodies) with increasing A. vera extract or aloin concentration was 
observed in all the four cases. Therefore, this experiment shows that A. vera extract or  
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Fig. 31. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG (D) and with 
varying concentration of A. vera extract for 10 days at 37oC. Lane 1 shows 
molecular weight markers (Genei); Lane 2 shows SOD (10 μg) that has not been 
incubated with glucose, MG or A. vera extract. Lanes 3, 4, 5 and 6 show SOD (10 μg) 
incubated for 10 days alone or with glucose, MG or a combination of glucose and MG 
and with 0, 10, 20 and 50 μg/ml A. vera extract, respectively 
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Fig. 32. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG (D) and with 
varying concentration of aloin for 10 days at 37oC. Lane 1 shows molecular weight 
markers (Genei); Lane 2 shows SOD (10 μg) that has not been incubated with 
glucose, MG or aloin. Lanes 3, 4, 5 and 6 show SOD (10 μg) incubated for 10 days 
alone or with glucose, MG or a combination of glucose and MG and with 0, 10, 20 
and 50 μM aloin, respectively. 
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Fig. 33. Effect of A. vera extract or aloin on the cross-reactivity (ELISA) of anti-
SOD antibodies with SOD incubated with glucose, MG or both. SOD (0.2 mg/ml) 
was incubated alone (Panel 1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) 
or combination of 0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the 
presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µg/ml of A. vera extract (A) or µM aloin 
(B). Each Panel also shows native SOD (0.2 mg/ml) alone in buffer that was not 
incubated at 37oC for any time period (■). Each value represents the average for two 
independent experiments performed in triplicates. 
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aloin protected the enzyme to some extent against the structural/chemical changes 
induced by incubation at 37oC and glycation with glucose, MG or a combination of both, 
and the protection increased with increasing concentration of A. vera extract or aloin. 
4.4.4. UV absorption studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of A. vera extract or aloin, a progressive 
decrease in absorbance at 280 nm with increasing A. vera extract (Fig. 34A, Panel 2, 3 
and 4, respectively) or aloin (Fig. 34B, Panel 2, 3 and 4, respectively) concentration 
was observed in all the three cases. SOD incubated alone for 10 days with increasing 
A. vera extract (Fig. 34A, Panel 1) or aloin (Fig. 34B, Panel 1) concentration (control) 
exhibited very slight decrease in absorbance at 280 nm. Therefore, A. vera extract or 
aloin protected the enzyme to some extent against the structural changes induced by 
glycation with glucose, MG or a combination of both, and the protection increased 
with increasing concentration of A. vera extract or aloin. However, the enzyme was 
still far from the structure of the native enzyme even at 50 µg or 50 µM concentration 
of A. vera extract or aloin, respectively, in all the three cases.  
4.4.5. Intrinsic fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of A. vera extract (Fig. 35A, Panel 2, 3 and 4, 
respectively) or aloin (Fig. 35B, Panel 2, 3 and 4, respectively), a progressive increase 
in fluorescence at 310 nm with increasing A. vera extract or aloin concentration was 
observed in all the three cases. The control exhibited insignificant increase in 
fluorescence at 310 nm (Fig. 35A and 35B, Panel 1). Therefore, again this experiment 
shows that A. vera extract or aloin protected the enzyme to some extent against the 
structural changes induced by glycation with glucose, MG or a combination of both, 
and the protection increased with increasing concentration of A. vera extract or aloin. 
However, it was observed that SOD incubated for 10 days at 37oC with glucose, 
without A. vera extract or aloin but with 1% DMSO showed fluorescence 
enhancement at 310 nm and not quenching (Fig. 35A and 35B, Panel 2 Column 2). 
Therefore, it appears that in the samples of SOD glycated by glucose in the presence 
of DMSO, the environment around the aromatic residues of the protein is somehow 
perturbed which affects their fluorescence. 
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Fig. 34. Effect of A. vera extract or aloin on the absorption changes induced in 
SOD due to glycation. Absorbance at 280 nm for samples of SOD (0.2 mg/ml) that 
were incubated in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl 
alone (Panel 1) and with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a 
combination of 0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the 
presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µg/ml of A. vera extract (A) or µM aloin 
(B). Each Panel also shows native SOD alone in buffer that was not incubated at 37oC 
for any time period (■). 
 
76 
 
  
 
 
 
 
 
Fig. 35. Effect of A. vera extract or aloin on the intrinsic fluorescence changes 
induced in SOD due to glycation. Fluorescence intensity at the excitation/emission 
wavelengths of 280/310 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 
mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 
0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose 
and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) 
and 50 (░) µg/ml of A. vera extract (A) or µM aloin (B). Each Panel also shows native 
SOD alone in buffer that was not incubated at 37oC for any time period (■). 
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4.4.6. AGEs specific fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of A. vera extract (Fig. 36A, Panel 2, 3 and 4, 
respectively) or aloin (Fig. 36B, Panel 2, 3 and 4, respectively), a progressive 
decrease in AGEs specific fluorescence at 450 nm with increasing A. vera extract or 
aloin concentration was observed in all the three cases. The control exhibited 
insignificant decrease in fluorescence at 450 nm (Fig. 36A and 36B, Panel 1). 
Therefore, A. vera extract or aloin protected the enzyme to some extent against 
formation of AGEs induced by glycation with glucose, MG or a combination of both, 
and the protection increased with increasing concentration of A. vera extract or aloin.  
4.4.7. ThT fluorescence studies 
Glycation of SOD by glucose, MG and both glucose and MG results in ThT 
fluorescence enhancement at 480 nm (formation of fibrils). When SOD is incubated 
for 10 days at 37oC with glucose, MG or both glucose and MG and increasing 
concentration of A. vera extract (Fig. 37A, Panel 2, 3 and 4, respectively) or aloin 
(Fig. 37B, Panel 2, 3 and 4, respectively), a progressive decrease in ThT fluorescence 
with increasing A. vera extract or aloin concentration was observed in all the three 
cases. The control exhibited insignificant decrease in ThT fluorescence at 480 nm 
(Fig. 37A and 37B Panel 1). Therefore, A. vera extract or aloin protected the enzyme 
to some extent against formation of fibrils induced by glycation with glucose, MG or 
a combination of both, and the protection increased with increasing concentration of 
A. vera extract or aloin.  
4.5. Protective effect of EA on the glycation of SOD with glucose or MG 
4.5.1. Activity studies 
The effect of EA on the activity of SOD glycated by 0.5 M glucose or 10 mM 
MG was studied. Fig. 38 shows the percentage remaining activity of SOD incubated 
for ten days at 37oC alone, and that incubated in the presence of glucose, MG or a 
combination of both and with increasing concentration of EA. SOD incubated for ten 
days alone with EA showed a slight increase in activity with increasing EA 
concentration (Fig. 38, Panel 1). The activity increased by 2.8% when the enzyme 
was incubated with 50 µM EA respectively as compared to the control (the sample  
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Fig. 36. Effect of A. vera extract or aloin on the fluorescent AGEs formed of SOD 
due to glycation. AGEs specific fluorescence intensity at the excitation/emission 
wavelengths of 350/450 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 
mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 
0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose 
and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) 
and 50 (░) µg/ml of A. vera extract (A) or µM aloin (B). Each Panel also shows native 
SOD alone in buffer that was not incubated at 37oC for any time period (■). 
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Fig. 37.  Effect of A. vera extract or aloin on the fibrils formed in SOD due to 
glycation. ThT fluorescence intensity at the excitation/emission wavelengths of 
440/480 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µg/ml of A. vera extract (A) or µM aloin (B). Each Panel also shows native SOD 
alone in buffer that was not incubated at 37oC for any time period (■). 
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Fig. 38. Effect of EA on the activity of SOD incubated with glucose, MG or both. 
SOD (0.2 mg/ml) was incubated alone (Panel 1), with 0.5 M glucose (Panel 2) or 10 
mM MG (Panel 3) or combination of 0.5 M glucose and 10 mM MG (Panel 4) for 10 
days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM EA. Each Panel 
also shows native SOD (0.2 mg/ml) alone in buffer that was not incubated at 37oC for 
any time period (■). The enzyme activity was then determined under standard assay 
conditions. Each value represents the average for three independent experiments 
performed in duplicates. 
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that had no EA). This slight increase in activity of SOD is believed to be due the 
antioxidant property of EA. SOD incubated with glucose, MG or a combination of 
both, and EA showed a greater increase in activity as compared to the enzyme that 
was not incubated with glucose or MG. The activity increased by 15.9, 13.7 and 
10.0% as compared to the control when the enzyme was incubated with glucose (Fig. 
38, Panel 2), MG (Fig. 38, Panel 3) or a combination of both glucose and MG (Fig. 
38, Panel 4), respectively, and 50 µM EA. This observed further increase in activity is 
believed to be due to the antiglycating activity of EA. The data clearly indicates that 
the increase in activity was more in the case of glucose than for MG or both MG and 
glucose. Therefore, EA is a more effective antiglycating agent for sugars/compounds 
that are milder glycating agents.  
4.5.2. SDS-PAGE  
The protective effect of EA on SOD fragmentation/cross-linking induced by 
glycation is seen in fig. 39. SDS-PAGE of SOD incubated for ten days in the absence 
of glucose or MG showed same staining intensity with increasing EA concentration 
(Fig. 39A). However, the enzyme incubated for ten days with glucose showed a more 
increase in staining intensity with increasing EA concentration (Fig. 39B). SOD 
incubated for ten days with MG (Fig. 39C) or a combination of both glucose and MG 
(Fig. 39D) exhibited a decrease in the bands corresponding to the cross-linked 
aggregates with increasing EA concentration. Infact in the case of MG alone, there 
was a slight increase in the band corresponding to the native enzyme with increasing 
EA concentration. Therefore, it is evident from SDS-PAGE analysis that EA 
protected SOD against fragmentation/cross-linking induced by glycation. 
4.5.3. ELISA 
Incubation of SOD alone or with glucose, MG and both glucose and MG 
results in a decrease in absorbance at 490 nm in ELISA indicating reduced cross-
reactivity with anti-SOD antibodies, which we believe is due to the 
structural/chemical modification of the epitopes of enzyme due to incubation at 37oC 
and by glycation. When SOD is incubated for 10 days at 37oC alone or with glucose, 
MG or both glucose and MG and increasing concentration of EA, a progressive 
increase in absorbance at 490 nm (cross-reactivity with anti-SOD antibodies) with 
increasing EA concentration (Fig. 40) was observed in all the four cases. Therefore,  
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Fig. 39. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG (D) and with 
varying concentration of EA for 10 days at 37oC. Lane 1 shows molecular weight 
markers (Genei); Lane 2 shows SOD (10 μg) that has not been incubated with 
glucose, MG or EA. Lanes 3, 4, 5 and 6 show SOD (10 μg) incubated for 10 days 
alone or with glucose, MG or a combination of glucose and MG and with 0, 10, 20 
and 50 μM EA, respectively. 
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Fig. 40. Effect of EA on the cross-reactivity (ELISA) of anti-SOD antibodies with 
SOD incubated with glucose, MG or both. SOD (0.2 mg/ml) was incubated alone 
(Panel 1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination of 
0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 
10 (≡), 20 (□) and 50 (░) µM EA. Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■). Each value 
represents the average for two independent experiments performed in triplicates. 
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this experiment shows that EA protected the enzyme to some extent against the 
structural/chemical changes induced by incubation at 37oC and glycation with 
glucose, MG or a combination of both, and the protection increased with increasing 
concentration of EA.  
4.5.4. UV absorption studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of EA, a progressive decrease in absorbance at 
280 nm with increasing EA (Fig. 41, Panel 2, 3 and 4, respectively) was observed in 
all the three cases. SOD incubated alone for 10 days with increasing EA concentration 
(control) exhibited very slight decrease in absorbance at 280 nm (Fig. 41, Panel 1). 
Therefore, EA protected the enzyme to some extent against the structural changes 
induced by glycation with glucose, MG or a combination of both, and the protection 
increased with increasing concentration of EA. However, the enzyme was still far 
from the structure of the native enzyme even at 50 µM concentration of EA, 
respectively, in all the three cases. 
4.5.5. Intrinsic fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of EA (Fig. 42, Panel 2, 3 and 4, respectively), 
a progressive increase in fluorescence at 310 nm with increasing EA concentration 
was observed in all the three cases. The control exhibited insignificant increase in 
fluorescence at 310 nm (Fig. 42, Panel 1). Therefore, again this experiment shows that 
EA protected the enzyme to some extent against the structural changes induced by 
glycation with glucose, MG or a combination of both, and the protection increased 
with increasing concentration of EA. However, it was observed that SOD incubated 
for 10 days at 37oC with glucose, without EA but with 1% DMSO showed 
fluorescence enhancement at 310 nm and not quenching (Fig. 42, Panel 2 Column 2). 
Therefore, it appears that in the samples of SOD glycated by glucose in the presence 
of DMSO, the environment around the aromatic residues of the protein is somehow 
perturbed which affects their fluorescence. 
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Fig. 41. Effect of EA on the absorption changes induced in SOD due to glycation. 
Absorbance at 280 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM 
sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 
0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose 
and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) 
and 50 (░) µM EA. Each Panel also shows native SOD alone in buffer that was not 
incubated at 37oC for any time period (■). 
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Fig. 42. Effect of EA on the intrinsic fluorescence changes induced in SOD due to 
glycation. Fluorescence intensity at the excitation/emission wavelengths of 280/310 
nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium phosphate 
buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M glucose (Panel 
2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 mM MG (Panel 
4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM EA. 
Each Panel also shows native SOD alone in buffer that was not incubated at 37oC for 
any time period (■). 
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4.5.6. AGEs specific fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of EA (Fig. 43, Panel 2, 3 and 4, respectively), 
a progressive decrease in AGEs specific fluorescence at 450 nm with increasing EA 
concentration was observed in all the three cases. The control exhibited insignificant 
decrease in fluorescence at 450 nm (Fig. 43, Panel 1). Therefore, EA protected the 
enzyme to some extent against formation of AGEs induced by glycation with glucose, 
MG or a combination of both, and the protection increased with increasing 
concentration of EA. 
4.5.7. ThT fluorescence studies 
Glycation of SOD by glucose, MG and both glucose and MG results in ThT 
fluorescence enhancement at 480 nm (formation of fibrils). When SOD is incubated 
for 10 days at 37oC with glucose, MG or both glucose and MG and increasing 
concentration of EA (Fig. 44, Panel 2, 3 and 4, respectively), a progressive decrease 
in ThT fluorescence with increasing EA was observed in all the three cases. The 
control exhibited insignificant decrease in ThT fluorescence at 480 nm (Fig. 44, Panel 
1). Therefore, EA protected the enzyme to some extent against formation of fibrils 
induced by glycation with glucose, MG or a combination of both, and the protection 
increased with increasing concentration of EA.  
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Fig. 43. Effect of EA on the fluorescent AGEs formed of SOD due to glycation. 
AGEs specific fluorescence intensity at the excitation/emission wavelengths of 
350/450 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µM EA. Each Panel also shows native SOD alone in buffer that was not incubated 
at 37oC for any time period (■). 
 
 
 
 
 
 
 
Fig. 44. Effect of EA on the fibrils formed in SOD due to glycation. ThT 
fluorescence intensity at the excitation/emission wavelengths of 440/480 nm for 
samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium phosphate buffer, 
pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M glucose (Panel 2) or 
10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 mM MG (Panel 4) 
for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM EA. Each 
Panel also shows native SOD alone in buffer that was not incubated at 37oC for any 
time period (■). 
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4.6. Protective effect of alliin on the glycation of SOD with glucose or MG 
4.6.1. Activity studies 
The effect of alliin on the activity of SOD glycated by 0.5 M glucose or 10 
mM MG was studied. Fig. 45 shows the percentage remaining activity of SOD 
incubated for ten days at 37oC alone, and that incubated in the presence of glucose, 
MG or a combination of both and with increasing concentration of alliin. SOD 
incubated for ten days alone with alliin showed a slight increase in activity with 
increasing alliin concentration (Fig. 45, Panel 1). The activity increased by 5.1% 
when the enzyme was incubated with 50 µM alliin respectively as compared to the 
control (the sample that had no alliin). This slight increase in activity of SOD is 
believed to be due the antioxidant property of alliin. SOD incubated with glucose, 
MG or a combination of both, and alliin showed a greater increase in activity as 
compared to the enzyme that was not incubated with glucose or MG. The activity 
increased by 15.1, 14.3 and 10.6% as compared to the control when the enzyme was 
incubated with glucose (Fig. 45, Panel 2), MG (Fig. 45, Panel 3) or a combination of 
both glucose and MG (Fig. 45, Panel 4), respectively, and 50 µM alliin. This observed 
further increase in activity is believed to be due to the antiglycating activity of alliin. 
The data clearly indicates that the increase in activity was more in the case of glucose 
than for MG or both MG and glucose. Therefore, alliin is a more effective 
antiglycating agent for sugars/compounds that are milder glycating agents. 
4.6.2. SDS-PAGE  
The protective effect of alliin on SOD fragmentation/cross-linking induced by 
glycation is seen in Fig. 46. SDS-PAGE of SOD incubated for ten days in the absence 
of glucose or MG showed same staining intensity with increasing alliin concentration 
(Fig. 46A). However, the enzyme incubated for ten days with glucose showed a more 
increase in staining intensity with increasing alliin concentration (Fig. 46B). SOD 
incubated for ten days with MG (Fig. 46C) or a combination of both glucose and MG 
(Fig. 46D) exhibited a decrease in the bands corresponding to the cross-linked 
aggregates with increasing alliin concentration. Infact in the case of MG alone, there 
was a slight increase in the band corresponding to the native enzyme with increasing 
alliin concentration. Therefore, it is evident from SDS-PAGE analysis that alliin 
protected SOD against fragmentation/cross-linking induced by glycation. 
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Fig. 45. Effect of alliin on the activity of SOD incubated with glucose, MG or 
both. SOD (0.2 mg/ml) was incubated alone (Panel 1), with 0.5 M glucose (Panel 2) 
or 10 mM MG (Panel 3) or combination of 0.5 M glucose and 10 mM MG (Panel 4) 
for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM alliin. Each 
Panel also shows native SOD (0.2 mg/ml) alone in buffer that was not incubated at 
37oC for any time period (■). The enzyme activity was then determined under 
standard assay conditions. Each value represents the average for three independent 
experiments performed in duplicates. 
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Fig. 46. SDS-PAGE of SOD incubated alone (A), with 0.5 M glucose (B), with 10 
mM MG (C) or a combination of 0.5 M glucose and 10 mM MG (D) and with 
varying concentration of alliin for 10 days at 37oC. Lane 1 shows molecular weight 
markers (Genei); Lane 2 shows SOD (10 μg) that has not been incubated with 
glucose, MG or alliin. Lanes 3, 4, 5 and 6 show SOD (10 μg) incubated for 10 days 
alone or with glucose, MG or a combination of glucose and MG and with 0, 10, 20 
and 50 μM alliin, respectively. 
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4.6.3. ELISA 
When SOD is incubated for 10 days at 37oC alone or with glucose, MG or 
both glucose and MG and increasing concentration of alliin, a progressive increase in 
absorbance at 490 nm (cross-reactivity with anti-SOD antibodies) with increasing 
alliin concentration (Fig. 47) was observed in all the four cases. Therefore, this 
experiment shows that alliin protected the enzyme to some extent against the 
structural/chemical changes induced by incubation at 37oC and glycation with 
glucose, MG or a combination of both, and the protection increased with increasing 
concentration of alliin.  
4.6.4. UV absorption studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of alliin, a progressive decrease in absorbance 
at 280 nm with increasing alliin (Fig. 48, Panel 2, 3 and 4, respectively) was observed 
in all the three cases. SOD incubated alone for 10 days with increasing alliin 
concentration (control) exhibited very slight decrease in absorbance at 280 nm (Fig. 
48, Panel 1). Therefore, alliin protected the enzyme to some extent against the 
structural changes induced by glycation with glucose, MG or a combination of both, 
and the protection increased with increasing concentration of alliin. However, the 
enzyme was still far from the structure of the native enzyme even at 50 µM 
concentration of alliin, respectively, in all the three cases. 
4.6.5. Intrinsic fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of alliin, a progressive increase in fluorescence 
at 310 nm with increasing alliin concentration was observed in all the three cases (Fig. 
49, panel 2, 3, and 4, respectively). The control exhibited insignificant increase in 
fluorescence at 310 nm (Fig. 49, panel 1). Therefore, again this experiment shows that 
alliin protected the enzyme to some extent against the structural changes induced by 
glycation with glucose, MG or a combination of both, and the protection increased 
with increasing concentration of alliin. The earlier results where fluorescence 
enhancement at 310 nm instead of quenching for SOD incubated for 10 days at 37oC 
with glucose and 1% DMSO were explained on the assumption that in the sample of 
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 Fig. 47. Effect of alliin on the cross-reactivity (ELISA) of anti-SOD antibodies 
with SOD incubated with glucose, MG or both. SOD (0.2 mg/ml) was incubated 
alone (Panel 1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination 
of 0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 
(♯), 10 (≡), 20 (□) and 50 (░) µM alliin. Each Panel also shows native SOD (0.2 
mg/ml) alone in buffer that was not incubated at 37oC for any time period (■). Each 
value represents the average for two independent experiments performed in 
triplicates. 
 
 
 
 
 
 
Fig. 48. Effect of alliin on the absorption changes induced in SOD due to 
glycation. Absorbance at 280 nm for samples of SOD (0.2 mg/ml) that were 
incubated in 20 mM sodium phosphate buffer, pH 7.4 containing 0.15 M NaCl alone 
(Panel 1) and with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or a combination 
of 0.5 M glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 
(♯), 10 (≡), 20 (□) and 50 (░) µM alliin. Each Panel also shows native SOD alone in 
buffer that was not incubated at 37oC for any time period (■). 
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Fig. 49. Effect of alliin on the intrinsic fluorescence changes induced in SOD due 
to glycation. Fluorescence intensity at the excitation/emission wavelengths of 
280/310 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µM alliin. Each Panel also shows native SOD alone in buffer that was not 
incubated at 37oC for any time period (■). 
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SOD glycated by glucose in the presence of DMSO, the environment around the 
aromatic residues of the protein is somewhat perturbed which affects the fluorescence. 
However, in the present experiment, alliin was dissolved in buffer and no DMSO was 
present in the sample, therefore as expected quenching was observed. Therefore, this 
proves our earlier assumption. 
4.6.6. AGEs specific fluorescence 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of alliin (Fig. 50, Panel 2, 3 and 4, 
respectively), a progressive decrease in AGEs specific fluorescence at 450 nm with 
increasing alliin concentration was observed in all the three cases. The control 
exhibited insignificant decrease in fluorescence at 450 nm (Fig. 50, Panel 1). 
Therefore, alliin protected the enzyme to some extent against formation of AGEs 
induced by glycation with glucose, MG or a combination of both, and the protection 
increased with increasing concentration of alliin.  
4.6.7.  ThT fluorescence studies 
When SOD is incubated for 10 days at 37oC with glucose, MG or both glucose 
and MG and increasing concentration of alliin (Fig. 51, Panel 2, 3 and 4, respectively), 
a progressive decrease in ThT fluorescence with increasing alliin was observed in all 
the three cases. The control exhibited insignificant decrease in ThT fluorescence at 480 
nm (Fig. 51, Panel 1). Therefore, alliin protected the enzyme to some extent against 
formation of fibrils induced by glycation with glucose, MG or a combination of both, 
and the protection increased with increasing concentration of alliin.  
4.6.8. CD studies 
Far-UV CD studies which were not possible for TQ, A. vera, aloin and EA due 
to DMSO in the samples which interfered with the measurements in this wavelength 
range, were possible for alliin as in this case no DMSO was present in the samples. 
Glycation of SOD by glucose, MG and both glucose and MG results in decrease in the 
negative ellipticity (secondary structural changes). When SOD is incubated for 10 
days at 37oC alone (control) or with glucose, MG or both glucose and MG and 
increasing concentration of alliin, a progressive increase in the negative ellipticity 
with increasing alliin concentration was observed in all the four cases (Fig. 52 Panel 
1, 2, 3 and 4, respectively). Therefore, alliin protected the enzyme to some extent  
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Fig. 50. Effect of alliin on the fluorescent AGEs formed of SOD due to glycation. 
AGEs specific fluorescence intensity at the excitation/emission wavelengths of 
350/450 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µM alliin. Each Panel also shows native SOD alone in buffer that was not 
incubated at 37oC for any time period (■). 
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Fig. 51. Effect of alliin on the fibrils formed in SOD due to glycation. ThT 
fluorescence intensity at the excitation/emission wavelengths of 440/480 nm for 
samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium phosphate buffer, 
pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M glucose (Panel 2) or 
10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 mM MG (Panel 4) 
for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 (░) µM alliin. Each 
Panel also shows native SOD alone in buffer that was not incubated at 37oC for any 
time period (■). 
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Fig. 52. Effect of alliin on the far-UV CD changes induced in SOD due to glycation. 
CD at 208 nm for samples of SOD (0.2 mg/ml) that were incubated in 20 mM sodium 
phosphate buffer, pH 7.4 containing 0.15 M NaCl alone (Panel 1) and with 0.5 M 
glucose (Panel 2) or 10 mM MG (Panel 3) or a combination of 0.5 M glucose and 10 
mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (♯), 10 (≡), 20 (□) and 50 
(░) µg/ml of alliin. Each Panel also shows native SOD alone in buffer that was not 
incubated at 37oC for any time period (■). 
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against the secondary structural changes induced by incubation at 37oC and glycation 
with glucose, MG or a combination of both, and the protection increased with 
increasing concentration of alliin. 
4.7. Activity studies on comparative antiglycating potential of TQ, aloin, EA, 
alliin, and quercetin 
Quercetin has been reported to be a potent natural inhibitor of glycation (Sero et 
al., 2013). Therefore, we compared the antiglycating potential of the natural 
compounds used in this study, TQ, aloin, EA and alliin with that of quercetin by 
activity measurements. The activity increased by 17.3, 18.2 and 11.0% as compared 
to the control when the enzyme was incubated with glucose, MG or a combination of 
both glucose and MG, respectively, and 50 μM  quercetin (Fig. 53). The comparative 
antiglycating potential of TQ, aloin, EA, alliin and quercetin by activity 
measurements is shown in Table 1. The compound showing the best antiglycating 
potential is quercetin and the one showing the least is TQ.  The order of decrease of 
antiglycating potential is: Quercetin > EA/alliin > aloin > TQ. However, examining 
the values, the antiglycating potential of EA and alliin appears to be comparable with 
that of quercetin.  
4.8. Conclusions 
The study shows that the natural products used in this study (TQ, A. vera, aloin, 
EA and alliin), which have previously been reported to have several beneficial 
pharmacological activities, also have antiglycating activity. The antiglycating activity 
appears to be better for mild glycating agents. These natural products also protect 
against potent glycating agents such as MG. These natural products have also been 
reported to have antidiabetic effects. This taken together with their antiglycating 
effect as observed in this study makes them effective antidiabetic products which can 
be used in treating diabetes and its complications. 
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Fig. 53. Effect of quercetin on the activity of SOD incubated with glucose, MG or 
combination of both glucose and MG. SOD (0.2 mg/ml) was incubated alone (Panel 
1), with 0.5 M glucose (Panel 2) or 10 mM MG (Panel 3) or combination of 0.5 M 
glucose and 10 mM MG (Panel 4) for 10 days at 37oC in the presence of 0 (#), 10 (≡), 
20 (□) and 50 µM (░) quercetin. Each Panel also shows native SOD (0.2 mg/ml) 
alone in buffer that was not incubated at 37oC for any time period (■). The enzyme 
activity was then determined under standard assay conditions. Each value represents 
the average for three independent experiments performed in duplicates. 
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Table 1: Comparative antiglycating potential of natural compounds. The activity 
increase as compared to the control when SOD was incubated with glucose, MG or 
combination of both glucose and MG and 50 μM natural compound is shown. 
 
Natural 
compound 
Activity increase when SOD was incubated with: 
 Glucose MG Glucose + MG 
TQ 9.6 7.7 6.2 
Aloin 14.6 10.1 9.8 
EA 15.9 13.7 10.0 
Alliin 15.1 14.3 10.6 
Quercetin 17.3 18.2 11.0 
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Glycation  plays  an  important  role  in various  oxidative  stress  related  diseases.  Superoxide  dismutase
(SOD)  constitutes  an essential  defense  against  oxidative  stress.  The  damage  caused  by  oxidative  stress  is
exacerbated  if the  antioxidant  enzymes  themselves  are  inactivated  by  glycation.  Thymoquinone  (TQ)  has
been reported  to have  various  pharmacological  activities.  Therefore,  the  glycation  of  SOD  by  glucose  or
methylglyoxal  (MG)  and  its protection  by  TQ has  been  investigated.  Incubation  of  SOD with  glucose,  MG
or both  at  37 ◦C  resulted  in a  progressive  decrease  in  the activity  of  the  enzyme,  and  a  parallel  decrease
in  the  amount  of protein  on  SDS-PAGE  gels  for glucose  incubated  SOD  and  formation  of high  molecular
weight  aggregates  for MG or both  glucose  and  MG incubated  enzyme.  TQ  offered  protection  against
glucose  or  MG  induced  loss  in  SOD  activity  and fragmentation/cross-linking.  The  antiglycating  activity  of
TQ appears  to  be better  for mild  glycating  agents.  It is  also  effective  in protecting  against  strong  glycating
agents,  more  when  the exposure  time  to the  glycating  agent  is  short.  TQ  has  also  earlier  been  reported
to  have  anti-diabetic  effects,  and this  along  with  the  observed  antiglycating  effect  makes  it an  effective
compound  against  diabetes  and its  complications.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Diabetes has become the most common metabolic disease
worldwide. Hyperglycemia has a key role in the diseases associated
with diabetic complications. Non-enzymatic glycation comprises a
complex series of reactions between reducing sugars and amino
groups of proteins, lipids and nucleic acids. During glycation, the
carbonyl groups of sugars react slowly with the free amino groups
yielding Schiff base. The Schiff bases undergo Amadori rearrange-
ment, and through a series of further rearrangements, cyclizations,
dehydrations, etc. form a variety of diverse compounds, collectively
described as advanced glycation end products (AGEs) [1,2]. AGE for-
mation is accompanied by the formation, among others of a number
of reactive oxygen species, -oxoaldehydes including MG,  that
Abbreviations: SOD, superoxide dismutase; TQ, thymoquinone; AGE, sadvanced
glycation end products; MG,  methylglyoxal; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis; NBT, nitro blue tetrazolium; PMS, phenazine
methosulfate.
∗ Corresponding author. Tel.: +91 571 2720 388; fax: +91 571 272 1776.
E-mail address: hinayounus@rediffmail.com (H. Younus).
1 These authors have contributed equally to this paper.
further react and damage the proteins and other important bio-
logical molecules. MG  reacts irreversibly with amino groups in
proteins, forming AGEs [3]. Glycation of proteins play an important
role in the development of physiological and pathophysiological
processes, such as aging, diabetes, atherosclerosis, neurodegener-
ative diseases, vascular diseases and chronic renal failure [4].
SODs are a family of metalloenzymes that catalyze the dismuta-
tion of superoxide radicals (O2−) into molecular oxygen and H2O2
mediated by alternate oxidation-reduction of metal ions present at
their active site [5,6]. Among the enzymes inactivated by glycation,
SOD constitutes the ﬁrst, and possibly, the most important line of
antioxidant defense, enabling cells to cope with lethal oxidative
environments. Exposure of SOD to glucose results in its deacti-
vation following site-speciﬁc and random fragmentation [7]. The
damage caused by oxidative stress is expected to be exacerbated if
the antioxidant enzymes themselves are inactivated by glycation.
Elevated levels of MG have been reported to adversely affect SODs
particularly against superoxide radicals. Exposure of SOD to MG  has
been shown to cause its covalent cross-linking associated with loss
of enzymatic activity [8].
Current anti-diabetic therapy is based on synthetic drugs that
very often have side effects [9]. Alternative medicines and natural
0141-8130/$ – see front matter ©  2014 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.ijbiomac.2014.01.001
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Accumulation  of  advanced  glycation  end  products  (AGEs)  in  tissues  and  serum  plays  important  roles  in
diabetes-associated  complications.  Therefore,  the  identiﬁcation  of  antiglycating  compounds  is  attracting
considerable  interest.  In this  study,  the structural  changes  associated  with  the glycation  of superoxide
dismutase  (SOD)  and  its protection  by thymoquinone  (TQ)  have  been  investigated  by  biophysical  tech-
niques.  Incubation  of  SOD  with  glucose,  methylglyoxal  (MG)  or both  at  37 ◦C  resulted  in  progressive
hyperchromicity  at 280  nm,  intrinsic  ﬂuorescence  quenching  at 310  nm,  decrease  in  negative  ellipticity
at  208  nm, AGE-speciﬁc  ﬂuorescence  enhancement  in  the  wavelength  range  400–480  nm  and  Thioﬂavin
T  (ThT)  ﬂuorescence  enhancement  at 480  nm  (ﬁbrillar  state  enhancement).  Therefore,  glycation  by glu-
cose or  MG  induced  both  tertiary  and  secondary  structural  changes  in  SOD and  formation  of AGEs  and
ﬁbrils.  The  changes  were  more  and  faster  with  MG  than with  glucose  since  MG  is a stronger  glycating
agent  than  glucose.  TQ  offered  protection  against  glucose  or MG-induced  glycation  of  SOD  as  observed
by  a reduction  in  the  structural  changes,  formation  of  AGEs  and  ﬁbrils.  Thus,  TQ can  be  used for  reducing
diabetic  complications  many  of  which  are  due  to protein  glycation.
©  2014  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Hyperglycaemia leading to the glycation of proteins, lipids and
nucleic acids has an important role in the development of diseases,
such as diabetes, atherosclerosis, neurodegeneration, chronic renal
failure and vascular diseases [1]. During glycation, reducing sugars
react with the amino groups of lysine side chains and the termi-
nal amino groups of proteins to form unstable Schiff bases which
rearrange to form more stable Amadori products (Fig. 1). These
products further undergo a complex series of chemical reactions
via dicarbonyl intermediates to a number of diverse compounds,
collectively designated as advanced glycation end products (AGEs)
[2,3] (Fig. 1). The post-Amadori products constitute highly reac-
tive -dicarbonyl intermediates including methylglyoxal (MG) that
further damage the proteins and other biomolecules. Increased lev-
els of MG have been reported in the blood of diabetic patients [4].
Abbreviations: SOD„ superoxide dismutase; TQ„ thymoquinone; AGEs„
advanced glycation end products; MG„  methylglyoxal; ThT„ thioﬂavin T; ROS„
reactive oxygen species; SDS–PAGE„ sodium dodecyl sulphate-polyacrylamide gel
electrophoresis; BCA„ bicinchoninic acid.
∗ Corresponding author. Tel.: +91 571 2720 388; fax: +91 571 272 1776.
E-mail address: hinayounus@rediffmail.com (H. Younus).
Protein glycation by MG,  unlike that of reducing sugars in mainly
arginine-directed, however, other amino acid residues like lysine,
histidine and cysteine are also modiﬁed [5].
Glycation causes the inactivation of superoxide dismutase (SOD)
[6,7]. SOD constitutes an important defence mechanism by which
cells counter the deleterious effects of reactive oxygen species
(ROS). Cu,Zn-SOD is a homodimeric enzyme, and in bovine erythro-
cyte SOD, each subunit is folded into eight stranded -barrel with
three major external loops [8]. The damage caused by oxidative
stress is expected to be greater if the antioxidant enzymes them-
selves are inactivated by ROS. Since restriction in the glycation has
been shown to alleviate complications associated with diabetes and
other related disorders, efforts continue to develop strategies that
inhibit the accumulation of ROS.
Black seeds (Nigella sativa)  (Fig. 2A) have been used exten-
sively in traditional folk medicine [9]. Seeds or their extracts
have antidiabetic, antihypertensive, antimicrobial, antiinﬂamma-
tory, antitumour, galactagogue and insect repellent effects [9–11].
Thymoquinone (TQ) (Fig. 2B) which is the main active compo-
nent of the volatile oil of black seeds also has antidiabetic activity
apart from possessing many other useful pharmacological activities
[12–14]. We  have recently shown by activity and sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS–PAGE) analysis
that TQ protects SOD against glycation [15]. The aim of the present
http://dx.doi.org/10.1016/j.ijbiomac.2014.06.003
0141-8130/© 2014 Elsevier B.V. All rights reserved.
